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The Role of Receptor Tyrosine Kinase Axl in Pancreatic Ductal Adenocarcinoma 
and Its Regulation by Hematopoietic Progenitor Kinase 1 
 
Publication No.______ 
 
Xianzhou Song, M.S. 
Supervisory Professor: Huamin Wang, M.D., Ph.D. 
 
Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive malignancies with 
less than 5% of five year survival rate. New molecular markers and new therapeutic 
targets are urgently needed for patients with PDA. Oncogenic receptor tyrosine kinase 
Axl has been reported to be overexpressed in many types of human malignancies, 
including diffuse glioma, melanoma, osteosarcoma, and carcinomas of lung, colon, 
prostate, breast, ovary, esophagus, stomach, and kidney. However, the expression and 
functions of Axl in PDA are unclear. We hypothesized that Axl contributes to the 
development and progression of PDA. We examined Axl expression in 54 human PDA 
samples and their paired benign pancreatic tissue by immunohistochemistry, we found 
that Axl was overexpressed in 70% of  stage II PDAs, but only 22% of benign ducts 
(P=0.0001). Axl overexpression was associated with higher frequencies of distant 
metastasis and was an independent prognostic factor for both poor overall and 
recurrence-free survivals in patients with stage II PDA (p = 0.03 and 0.04). Axl silencing 
by shRNA in pancreatic cancer cell lines, panc-28 and Panc-1, decreased tumor cell 
migration and invasion and sensitized PDA cells to apoptosis stimuli such as γ-irradiation 
vi 
 
and serum starvation. In addition, we found that Axl-mediated Akt and NF-κB activation 
and up regulation of MMP2 were involved in the invasion, migration and survival of 
PDA cells. Thus, we demonstrate that Axl plays an important role in the development and 
progression of PDA. Targeting Axl signaling pathway may represent a new approach for 
the treatment of PDA. 
To understand the molecular mechanisms of Axl overexpression in PDA, we found that 
Axl expression was down-regulated by hematopoietic progenitor kinase 1 (HPK1), a 
newly identified tumor suppressor in PDA. HPK1 is lost in over 95% of PDAs. 
Restoration of HPK1 in PDA cells down-regulated Axl expression. HPK1-mediated Axl 
degradation was inhibited by leupeptin, baflomycin A1, and monensin, suggesting that 
HPK1-mediated Axl degradation was through endocytosis-lysosome pathway. HPK1 
interacted with and phosphorylated dynamin, a critical component of endocytosis 
pathway. Overexpression of dominant negative form of dynamin blocked the HPK1-
mediated Axl degradation. Therefore we concluded that HPK1-mediated Axl degradation 
was through endocytosis-lysosome pathway and loss of HPK1 expression may contribute 
to Axl overexpression in PDAs.   
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CHAPTER 1: Backgrounds  
 
Pancreatic cancer 
  
Pathology of pancreatic cancer 
Pancreatic cancer is one of the most malignant diseases. Pancreatic cancer is ranked as 
fourth leading cause for all cancer related death in United States 1-3. In 2010, about 
43,140 new pancreatic cancer cases was expected; and about 36,800 pancreatic cancer 
patients was predicted to die from this disease 1. Only 24% of pancreatic patients can 
survive one year or more from the date of diagnosis. Overall 5 year survival rate is less 
than 5% 1-3. The absence of effective diagnostic markers for early stage pancreatic cancer 
partially counts for the high mortality. Most diagnosed pancreatic cancer patients have 
advanced diseases or distant metastasis 4, 5. More desperate reality is that there are no 
effective treatments for pancreatic cancer 4, 5. Traditional chemotherapy and radiation 
treatment have very minor impact on overall survival rate 6-10. According to 
epidemiologic studies on pancreatic cancer has identified smoking, diabetes, alcohol, 
pancreatitis, obesity, age (more than 60 year), genetic predisposition, hereditary disorders, 
and family history as risk factors for pancreatic cancer 11-16. 
 
Based on cellular origin, pancreatic cancer can be classified as exocrine or endocrine 
tumor. Exocrine tumors include pancreatic ductal adenocarcinomas (PDAs), cystic 
tumors, and cancer of the acinar cell origin. Endocrine tumors include gastrinomas, 
insulinomas, somatostatinomas, VIPoma, glucagonomas, PPomas, GNRHomas, 
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ACTHoma and other non-functional tumors 17-20. Pancreatic ductal adenocarcinoma 
(PDA) accounts for 90% of diagnosed pancreatic cancers11,  
 
Previous studies have shown that PDA arises from pancreatic intraepithelial neoplasia 
(PanIN), intraductal papillary mucinous neoplasm and mucinous cystic neoplasm. PanINs 
are microscopic lesions with neoplastic proliferation of epithelial cells, involving small 
pancreatic ducts 21-23. PanIN can be classified as PnaIN-1(A/B), PanIN-2, and PanIN-3, 
according to the degree of cellular atypia and architecture atypia 21-23. PanIN-1 represents 
ductal lesions with minimal nuclear atypia; correspondingly, PanIN-3 represents severe 
dysplasia or carcinoma in situ 24.  
 
Genetic alterations in pancreatic cancer 
More than 90% of PDAs have KRas point mutation 25, 26, and most KRas mutations are 
happened at codon 12 27. KRas is a GTPase. When bond to GTP, KRas is activated and 
functions as signaling molecular for many growth receptors 28. KRas-GTP activates 
down-stream signaling including mitogen-activated protein kinase (MAPK), 
phosphoinositide-3-kinase (PI3K), and serine/threonine protein kinase Akt pathways 29-31. 
Just like other members of Ras family, KRas has intrinsic GTP hydrolysis activity. When 
GTP is converted to GDP, the signaling function of KRas is switched off 32. However, 
when KRas 12th amino acid Gly(G) is mutated to Valine(V) or Asp(D), the GTPase 
activity is inactivated. Mutated KRas constitutively binds to GTP, and is always at an 
activation status 33, 34. Other frequently amplified oncogenes consist of Akt2, C-Myc, 
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MyB, and EGFR 35. The occurring rate of above gene amplification varied from 10% to 
30% of all pancreatic patients 36-38.  
 
During the development and progression of PDA, a group of crucial tumor suppressor 
genes are frequently inactivated in pancreatic cancer, due to chromosomal deletion or 
mutation. CDKN2A/p16 is inactivated in almost all PDAs, by homozygous deletion, 
intragenic mutation or promoter hypermethylation 39-41. Protein p16 inhibits the cell cycle 
G1/S transition by binding to cyclin-dependent kinases Cdk4 and Cdk6 42-45.  Moreover, 
loss of p16 causes abnormal phosphorylation of retinoblastoma protein (Rb). Highly 
phosphorylated Rb will promote cell cycle progression 43, 46. Another frequently 
inactivated tumor suppressor gene in pancreatic cancer is TP53.  About 55–75% of PDAs 
have inactivated TP53 47, 48. TP53 inactivation always starts from intragenic mutation of 
one allele, and ends with the loss of the second allele by chromosome deletion 48. TP53 is 
called as guardian of genome. When DNA is damaged, a DNA repair pathway can be 
triggered by TP53. TP53 induces cell cycle arrest and cell apoptosis, which insure the 
cells, with DNA damage, to repair the DNA or die 47, 49-51. Inactivation of DPC4/SMAd4, 
by either homozygous deletion or mutation, is detected in about 55% of pancreatic cancer 
patients 21, 52, 53. SMAD4 is an important down-stream component of TGFβ pathway, 
which has inhibitory function on normal cell growth 54, 55. Other less often mutated tumor 
suppressor genes include BRCA2, MKK4, STK11, ALK1 and TGFBR 56-58.  
 
The development of PDAs is a process for accumulation of genetic alterations. Telomere 
shortening and KRas oncogenic mutation occur in early precursor lesion PanIN-1A 59. 
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The p16 inactivation was started to be observed on PanIN-1B lesions, with a steady 
increasing rate on higher grade lesions 60. SMAD4, TP53, and BRAC2 inactivation 
usually appears on high grade lesion PnaIN-3 and late invasive adenocarcinoma 21, 59, 61. 
The pool of identified genetic alterations is steady increasing. The on-going function 
genome and whole cancer genome sequencing will help to reveal new altered genes,         
 
Pancreatic cancer in mouse model 
Pancreatic cancer development and progression has been recaptured in mouse models, 
which greatly extended our understandings about the molecular and cellular mechanisms 
of pancreatic cancer oncogenesis and development. Hingorani et al created a PDX1-Cre, 
LSL-KRasG12D mouse 62. Pancreas/duodenum homobox protein 1 (PDX1) is a pancreas 
specific transactivator, determining the pancreatic cell fate 63. PDX1-Cre construct 
ensures that Cre is specifically expressed in mouse pancreas. LSL-KRasG12D has an 
endogenous mouse KRas promoter, ensuring that the KRasG12D expression levels 
mimic the physiological endogenous KRas expression levels. PDX1-Cre, LSL-
KRasG12D mice fully recaptured the full spectrum of development of human PDA 62. 
PanIN lesions, from PanIN-1, PanIN-2 to PanIN-3, and spontaneous invasive PDA 
developed in PDX1-Cre, LSL-KRasG12D mice. This mouse model established the role 
of KRasG12D in initiating the PanIN lesions and PDAs.    
 
The roles of tumor suppressor genes, like p16 (INK4a) and p53, have also been examined 
in mouse models.  Deficiency of either p16 (INK4a), or p53 alone failed to induce 
pancreatic lesions in mouse. However, in the context of PDX1-Cre, LSL-KRasG12D 
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mouse, loss of p16 (INK4a), or p53 mutation caused rapid emergence of PanIN lesions, 
invasive and metastatic PDAs 64 65.  These mouse models further confirmed that tumor 
suppressor functions of p16 and p53 in the KRasG12D initiated pancreatic cancer 
development. Ji et al developed an elastase-Cre, cLGL-KRasG12V transgenic mouse 66. 
Elastase is a pancreas acinar cell specific gene, driving acinar cell specific expression of 
Cre. cLGL-KRasG12V ensure overexpression of KRasG12V. Interestingly, elevated 
KRas activity quickly produced chronic pancreatitis, mouse PanINs, pancreatic ductal 
adenocarcinoma, and cystic papillary carcinoma. Based on above findings, a novel model 
of pancreatic cancer development was proposed. Elevated Ras activity will induce acinar-
to-ductal metaplasia and inflammation. Inflammation will further cause genome 
instability, which will let loss of tumor suppressor genes occur. Above models suggest a 
key role of KRas in pancreatic diseases, including pancreatitis, PanIN lesions, and 
pancreatic cancer 66, 67. The established mouse models will provide us a good tool to 
explore the molecular mechanisms in pancreatic cancer development and progression, 
and to identify new diagnostic markers and therapeutic targets for PDA.  
 
Axl 
 
Molecular biology of Axl 
According to human genome sequence, there are about 90 tyrosine kinase genes 
identified. Among them, 58 genes encode different receptor tyrosine kinase (RTK). 
Based on amino acid sequence similarity in the kinase domain and extracellular region, 
58 RTKs were divided into 20 subfamilies 68. A typical RTK contains an extracellular 
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region and an intracellular tyrosine kinase domain. The unique feature of RTK makes it 
function as communicating bridge between extracellular environment and cell 69-71. In 
general, RTK activity is triggered by secreted ligands. After binding of a RTK specific 
ligand, RTK will dimerize or oligmerize, and is activated by conformational change and 
trans-autophosphorylation in cytoplasmic kinase domain. The phospho-Tyr residue(s) on 
RTK cytoplasmic tail will provide docking sites for recruiting down-stream molecules, 
like adaptor proteins containing Src homology 2 (SH2) domain or phosphotyrosine 
binding (PTB) domain 72. Once adaptor proteins are recruited by RTK, the down-stream 
signaling(s) is initiated 69-71. RTK was found to participate in cell growth, survival, 
differentiation, motility, and almost all other cellular processes, in either normal 
condition or disease status 69-71. Deregulated RTKs play important roles in cancer 
development and treatment 73, 74. 
 
Receptor tyrosine kinase Axl is also called UFO, or Ark receptor 75 {Janssen, 1991 #423, 76. Axl, 
Tyro-3 together with Mer constitutes an Axl receptor family, or TAM family 77, 78-80. Axl 
receptor family is featured with a unique KW(I/L)A(I/L)ES amino acid motif in 
cytoplasmic kinase domain, and 2 immunoglobulin-like (IgL)  domains followed with 2 
fibronectin type III (FNIII) domains in extracellular region, seeing figure 1 75, 77, 78-81. Axl 
gene encodes a protein with molecule weight of 97 KDa. However, Axl protein displays 
multiple bands with size between 120 and 140 KDa on SDS-PAGE, due to extensive 
post-translational modification 75. 
 
Axl receptor ligand, Gas6 
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Soon after identification of Axl, growth arrest specific 6 (Gas6) was identified as a ligand 
for Axl by an affinity matrix containing extracellular part of Axl 82. Almost at the same 
time, Protein S, a Gas6 homologue, was identified as another ligand for Axl 83. Gas6 and 
Protein S were confirmed as ligands for all members of Axl receptor family 84, 85. Protein 
S shares 43% identical amino sequence with Gas6 83. Moreover, Protein S has same 
domain structure as Gas6 83.  Gas6 has a glutamic acid rich domain in N-terminal, four 
EGF-like repeats in middle region, and 2 globular laminin G-like (LG) domains in C-
terminal 86. Whole molecular weight is about 75 KDa 86. Reactive Gas6 relies on 
carboxylation at N-terminal glutamic acid residues, through a vitamin K-dependent 
reaction 85, 87. X-ray crystallography studies revealed that two Gas6 molecules can form a 
tetramer with two Axl molecules 88. Each Gas6 LG1 domain simultaneously contacts 
immunoglobulin-like (IgL) domain 1 of first Axl and immunoglobulin-like (IgL) domain 
2 of second Axl. Two Axl molecules are bridged by two Gas6 molecules. There is no 
direct Axl/Axl, or Gas6/Gas6 contacts, seeing figure 1 88.   
 
Axl activation and downstream signaling 
Axl activation can follow a typical approach adopted by other RTKs. When ligand Gas6 
binds to Axl, Axl tyrosine phosphorylation is detectable 82. After mutational analysis of 
tyrosine residues on Axl C-terminal, tyrosine residues (Y-779, Y-821, and Y-866) were 
proposed as auto-phosphorylation sites. Mutation on above tyrosine sites blocked 
interaction with down-stream signaling molecules, like Grb2, phospholipase Cγ (PLCγ), 
p85 subunits of PI3K, c-src and lck 89.  
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Axl activation may also be completed through a ligand-independent approach. 
Overexpression of Axl in Drosophila S2 cells caused cell aggregation through Axl 
homophilic binding 90. Axl tyrosine phosphorylation was induced by Axl overexpression, 
even no additional Gas6 was added 90. 
 
Activated Axl can stimulate several pathways which are involved in cell proliferation, 
survival and migration. Early studies by introducing chimeric EGFR/Axl receptor into 
leukemia 32D cells revealed that a MAPK/ERK pathway was activated to promote cell 
proliferation 91. Adaptor proteins Grb2 and Shc bond to chimeric EGFR/Axl, when cells 
were stimulated with EGF protein. ERK activation by Axl require adaptor protein Grb2 
and Shc 91. Ectopic expression of dominant negative ERK in 32D cells abrogated Axl 
mediated cell proliferation91. Blocking Ras activity by antibody microinjection ablated 
Gas6 induced mitogenesis of NIH3T3 cells 92. Phosphatidylinositol 3-kinase (PI3K)/Akt 
pathway was revealed to be a major survival pathway that is activated by Gas6/Axl 
signaling 92, 93, 94. Introducing dominant negative AKT (DN-AKT) into NIH3T3 cells 
blocked its Gas6 stimulated survival under serum starvation condition 92. Gas6 stimulated 
JNK pathway through PI3/Akt pathway. Blocking Akt pathway by inhibitors also 
blocked JNK pathway 92. Rac/Rho protein was also involved in Gas6 stimulated cell 
survival. Gas6 mediated PI3K activation may activate JNK through Rac/Rho protein 92. 
Transcription factor NF-κB was another signaling stimulated by Gas6 activated PI3/Akt 
survival pathway 95, 96. Gas6 stimulation caused IκB degradation, which make NF-κB 
accumulation in nuclear. Activated NF-κB promoted the transcription of anti-apoptosis 
factor Bcl-x and Bcl-295, 96. In addition, P13K pathway activated by Gas6/Axl signaling 
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was also involved in cell migration. Gas6/Axl signaling can cause Gonadotropin-
releasing hormone (GnRH) neuron migration through activating Rac  p38 
MAPK  MAPKAP kinase 2  HSP25 pathway, which is mediated by PI3K 97, 98. 
Moreover, Other molecules activated by Gas6/Axl signaling includes Src, PLCγ, and Nck 
and RanBPM 89, 99. The signaling pathways activated by Gas6/Axl signaling are 
summarized in figure 1. 
 
10 
 
Figure 1. The schematic presentation of Axl structure and summary of some Axl 
down-stream signaling  
Axl has a typical tyrosine kinase domain in intracellular part, and two each of 
immunoglobulin-like (IgL) and fibronectin type III (FNIII) motifs in extracellular part. 
Ligand Gas6 specifically binds to IgL motifs and facilitates Axl dimerization. Dimerized 
Axl is activated by mutually trans-phosphorylating the Tyrosine on C-terminal. The 
phosphorylated Tyrosine sites provide docking sites for some down-stream signaling. Axl 
can activate Ras/MAPK and Src/Lck pathways which contribute to cell proliferation. Axl 
also can activate PI3K/Akt pathway to promote cell survival and invasion. Moreover, Axl 
is involved in Rac/p38 signaling which regulates the cell motility.          
11 
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Axl functions in normal cells 
So far many cellular functions of Gas6/Axl signaling have been explored. Regulating the 
immune response is one major function of Axl and the other two TAM family members. 
Triple knock-out mice of TAM receptors  developed a spleen of 10 times bigger than a 
normal one 100. Aberrant lymphocyte proliferation was observed 100. TAM triple mutants 
eventually developed autoimmunity disease accompanied by hyperactivation of antigen 
presenting cells (APCs) like macrophage and dendritic cells 100. Symptoms related to 
rheumatoid arthritis, systemic lupus erythematosis, pemphigus vulgaris could be found in 
TAM triple mutants 100. Excessive TNF-α production was a driving factor for above auto-
immune diseases 100, 101, 102. Moreover, TAM mutants displayed a defect in phagocytosis 
103. Mer-/- macrophage could not engulf apoptotic cells 103. During the process of clearing 
the apoptotic cells, Gas6 or Pro S binds to phosphatidylserine (PtdSer) which is 
specifically presented on the surface of apoptotic cell 104. After Gas6/Pro S binding to 
TAM family proteins on macrophages, a signaling cascade will be trigged to rearrange 
the actin cytoskeleton for phagocytosis 104-108. Due to ineffective phagocytosis activity, 
TAM mutants eventually developed a degenerative phenotype in testis. The depletion of 
sperm cells turn mouse to be sterile 109. Axl, Tyro-3, and Mer are also required for normal 
function of natural killer (NK) cells 110, 111. NK cells with high Axl expression are more 
cytotoxic. Axl-/- NK cells showed a 90% reduction in killing activity111. After cytokine 
stimulation, NK cells with TAM triple mutants had less IFN-γ production. TAM are 
involved in NK cell differentiation 111.  
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The role of Gas6/Axl signaling in vascular smooth muscle cells (VSMCs) received a lot 
investigation since Axl was cloned. Gas6 and Axl expression were increased at the sites 
of vascular injury. Gas6 attracted VSMCs but not the one with overexpressed Axl 
dominant negative form (Axl-DN) mutant migrated to injury sites 112. Moreover, 
Gas6/Axl signaling protected VSMCs from serum starvation caused apoptosis 113. In 
VSMCs, a PI3K/AKT survival pathway could be activated by Gas6/Axl signaling 113.         
 
Axl functions in cancer 
Axl was initially identified as an oncogene from patients with chronic myelogenous 
leukemia (CML). Transient Axl overexpression caused NIH3T3 cells transformation 114. 
Later soon, more and more evidences of Axl as an oncogene were obtained from different 
types of cancer, including leukemia, colon, prostatic, breast, gastric, renal and lung 
cancers 115. In past years, more details about Axl functions on cancer progression have 
been elucidated. Axl functions in cancer are majorly focused on cell migration/invasion, 
metastasis, cell survival/proliferation/tumor growth, and angiogenesis.  
 
Role of Gas6/Axl signaling in cell migration, invasion and metastases  
Gas6/Axl signaling can induce migration in both normal and cancer cells. Extracellular 
Gas6 functioned as chemo-attractant and induced migration of vascular smooth muscle 
cells (VSMC). Overexpression of Axl in VSMC enhanced Gas6 induced migration; 
whereas, Dominant negative Axl (Axl-DN) reduced Gas6 induced migration 112. 
Gas6/Axl signaling was proposed to play a role in atherosclerosis and restenosis, where 
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VSMC migration was involved 116. Migration of Gonadotropin-releasing hormone 
(GnRH) neuron, as well as dendritic cells are also regulated by Gas6/Axl signaling 97, 117.  
 
In brain tumor, Axl dominant negative form (Axl-DN) inhibited glioma diffuse-invasive 
growth in a xenograft mouse model 118. The migration and invasion rate was significantly 
lower in glioma cells harboring Axl-DN 118. Inhibition of Gas6/Axl signaling decreased 
filopodia formation and make cells turn to a round shape. Similar effects caused by Axl 
inhibition were also found in mesotheliomas, hepatocarcinoma and cervical cancer 119-121.  
Gas6 induced GnRH neuron migration was accompanied with cytoskeleton 
reorganization, and lamellipodia formation 97, which could be blocked by Axl-DN. 
Gas6/Axl signaling can activate Rac GTPase/p38 MAPK /MAPKAP kinase 2/HSP25 
pathway. Blocking either Rac GTPase or p38 MAPK stopped the actin cytoskeletal 
remodeling, as well as GnRH neuron migration 97. In breast cancer cells, overexpression 
of Axl can activate MEK/ERK, NF-κB pathway. NF-κB cooperated with Brg-1, a subunit 
of SWI/SNF chromatin complex, to induce transcription of matrix metalloproteinase 9 
(MMP-9), which was required for Axl caused cancer cell invasion. On other hand, Axl-
DN inhibited the MMP-9 expression and cell invasion both in vitro and in vivo 122, 123. 
Epithelial-to-mesenchymal transition (EMT) is considered as a critical beginning step for 
cancer progression and metastasis. During EMT process, cells lose polarity and adhesion, 
and gain mobility 124. Interestingly, Axl participates in EMT process through different 
ways. In breast cancer, vimentin induced EMT and migration can be blocked by Axl 
shRNA. Vimentin controlled Axl expression 125. In acute myeloid leukemia cells, 
ectopically overexpressing Axl increased expression of Twist, which is involved in EMT. 
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In pancreatic cancer cells, silencing Axl reduced the expression of Twist, Slug, and Snail, 
which can repress E-cadherin expression 126. Repression of E-cadherin is a crucial step 
for most EMT processes 124.  
 
Role of Gas6/Axl signaling in cell survival, proliferation and tumor growth  
Axl can contribute to tumor growth by promoting either cell survival, proliferation, or in 
combination. Axl was firstly recognized for its transformation activity in NIH3T3 cells. 
Gain of self-sustaining proliferation or extra cell survival signals is a typical process of 
cell transformation 75. Later on, Gas6 was observed to accelerate NIH3T3 cell entry into 
S phase, and cell recovery from serum starvation, suggesting Axl can contribute to both 
cell proliferation and survival 93. Gas6 activates Akt and Src kinases, whose inhibition 
blocked Gas6 induced cell survival and proliferation 93. In addition, NF-κB activation by 
Gas6 was required for Gas6 endowed NIH3T3 cell survival 95. Gas6/Axl signaling 
mediated cancer cell proliferation and survival are also observed on ocular melanoma, 
brain tumor, kaposi sarcoma, and mesothelioma 118, 120, 127, 128. Interestingly, in prostate 
carcinoma, Gas6/Axl signaling induced cell proliferation, but not protected cells from 
serum starvation caused apoptosis 129. Gas6 can activate both Akt and MEK in prostate 
carcinoma cells; however, only MEK activation is essential for Gas6 induced cell 
proliferation 129. Axl silencing had no effects on cutaneous squamous cell carcinoma 
(SCC) cell proliferation, but made cells sensitize to UV treatment. Axl silencing 
significantly altered the behavior of several apoptosis related molecular. Pro-apoptotic 
molecules Bad, Bax and Bak were more easily activated. Caspase activation and 
cytochrome C release were enhanced 130.    
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Gas6/Axl signaling was also found to be able to protect normal cells from apoptosis 
stimuli. Gas6 promoted GnRH neuronal cell survival during serum starvation by 
activating Akt and ERK pathways 131. Gas6 significantly reduced the amount of vascular 
smooth muscle cell (VSMC) in apoptosis, which was caused by serum deprivation. Gas6 
activated Akt but not ERKwas required for VSMC survival 113. Gas6/Axl signaling kept 
the hepatic stellate cells (HSC) survival during CCl4 induced rat liver injury 132. Again, 
Gas6 activated PI3K/Akt pathway played a role in HSC survival 132.   
 
Role of Gas6/Axl in angiogenesis 
Accompanying the tumor growth, new blood vessels will be generated to provide 
nutrition and oxygen. The genesis of new blood vessel is called angiogenesis. The 
structure of freshly generated blood vessel can be described as vascular smooth muscle 
wall lined outside of endothelium cells. Gas6/Axl signaling can promote vascular smooth 
muscle cell (VSMC) survival and migration 112, 113, which are required for angiogenesis. 
Moreover, Gas6/Axl signaling can also promote survival for umbilical vein endothelial 
cells (HUVECs) 133. Gas6 prolonged survival of endothelial cells after depletion of 
growth factors. Gas6 also protected endothelial cells from TNFα induced death 133.  The 
role of Gas6/Axl signaling in angiogenesis was also observed in a breast cancer xenograft 
mouse model 134. Axl silencing significantly reduced the amount of endothelial cells in 
breast cancer xenograft mouse model. Axl silencing blocked the endothelial tube 
formation in HUVEC culture plate. Furthermore, Axl inhibition blocked HUVEC 
proliferation 134. The role of Axl in angiogenesis was further confirmed by using Axl 
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specific inhibitor R428, which can block vascular endothelial growth factor (VEGF)–
induced corneal neovascularization in breast cancer xenograft mouse model 135.  
 
Therapeutic significance of Axl 
Since, in many types of cancer, Axl overexpression correlated well with cancer 
progression and metastasis, and inversely with overall patient survival rate, Axl can be 
used as a prognostic marker 121, 123, 136-141. Axl up-regulation is one of the major molecular 
events contributing to the cancer progression. Down regulation of Axl protein levels can 
be an approach to treat cancer. SiRNA or shRNA provided an efficient way to silence 
Axl expression. When breast cancer cell line MDA-MB-231 was introduced with Axl 
specific shRNA (shAxl), mouse xenograft growth of MDA-MB-231 was significant 
slower than vector alone control134. ShAxl also significantly blocked ovarian cancer 
metastasis in a mouse xenograft model123. Similar to the shAxl data, in both non-small 
cell lung cancer (NSCLC) and breast cancer, miR-34a and miR-199a/b was found to 
targeting Axl. Ectopic expression of above miRNA caused less migration, invasion and 
metastasis of cancer cells 142, 143. Since the tyrosine kinase activity is crucial for Axl 
oncogenic functions, developing Axl specific kinase inhibitor can be ideal strategy for 
cancer treatment. Amuvatinib (MP-470) binds to Axl very well (Kd=0.8µM). Treating 
gastrointestinal stromal tumor cells with MP-470 comprised its resistance to imatinib, 
which is a specific inhibitor for tyrosine kinases Abl, c-kit, and platelet-derived growth 
factor receptor (PDGFR) 144. Bosutinib (SKI-606) and R428 significantly reduced the 
breast cancer metastasis and prolonged model mouse survival 135, 145. R428 is specifically 
screened for inhibiting Axl kinase 135. The therapeutic effects of Bosutinib (SKI-606) and 
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R428 were also demonstrated in killing chronic lymphocytic leukemia (CLL) cells 99. Axl 
inhibitor DP-3975 greatly reduced the potential of migration and invasion in 
mesothelioma cells 90. Besides targeting the kinase enzymatic center, people have tried 
using anti-Axl monoclonal antibody to block Axl function. Axl mAbs 3G9 and 8B5 
blocked its binding to ligand Gas6, and inhibited the NSCLC tumor growth in xenograft 
mouse model 146. One more option to antagonize Gas6/Pro S binding to Axl is to add 
soluble extracellular part of Axl (Axl-Fc) to cancer cells 84, 147.  
 
Hematopoietic progenitor kinase 1 (HPK1) 
 
Hematopoietic progenitor kinase 1 (HPK1) is a serine/threonine kinase, having a STE20-
like kinase domain. HPK1 was firstly cloned from human fetal liver cDNA library 35, 148. 
Based on sequence homology, HPK1 is composed of a typical serine/threonine kinase 
domain in N-terminal region, four proline rich motifs in middle region, and a citron 
homology domain in C-terminal region 35. There are 28 serine/threonine kinases in 
mammalian share similar nuclear acid sequence with yeast kinase STE20 149. Since 
STE20 in yeast can activate MAP kinase pathway through activate Ste11p (MAP3K), 
STE20 is also named as MAP4K. In same way, HPK1 is called as MAP4K1 35. HPK1 is 
mainly expressed in hematopoietic cells 35, which was demonstrated by Northern Blotting 
assay.  
 
The role of HPK1 in immune system 
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Since HPK1 was originally found in hematopoietic cells 35, the role of HPK1 in immune 
system received extensive investigation. HPK1 is involved in the development of several 
kinds of immune cells. HPK1 functions as negative regulator of dendritic cell activation 
150. In HPK1 deficient mice, enhanced antigen presentation was observed. HPK1-/- bone 
marrow dendritic cells (BMDCs) obtained superior antigen presentation capability, which 
was reflected by more T cells in response 150. In consistent with superior activity of 
BMDCs, the activation markers, IL-12, IL-1β, TNF-α, and IL-6 were significantly 
increased in HPK1-/- BMDCs, when cells were stimulated with Lipopolysaccharide (LPS). 
The major reason for increased activity of HPK1-/- BMDCs is due to enhanced survival of 
BMDCs 150.  
 
HPK1 is also a negative regulator of T cell mediated immune response 151. HPK1-/- T 
cells were hyperproliferative when they were stimulated with anti-CD3 antibody, which 
activated T cell receptor (TCR) signaling. HPK1-/- T cells did not obtain extra survival 
potential when stimulated with anti-Fas or dexamethasone. HPK1-/- mice showed superior 
T helper type 1 and 2 responses and expressed more IL-2, IL-4 and IF-γ cytokines. 
HPK1-/- mice also showed aggravated autoimmunity, accompanied with hyper 
proliferation of autoreactive T cells 151.  HPK1 could down regulate T cell immune 
response through increasing T cell apoptosis after T cell activation. When CD4+ T cells 
were overexpressed with HPK1, a significant increased apoptosis rate was observed after 
TCR activation with anti-CD3 antibody. HPK1 also enhanced EL-4 thymoma apoptosis 
when cells were suffered with reactive oxygen species (ROS), which was introduced by 
adding H2O2 152.   
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HPK1 plays an important role in TCR signaling. Four proline rich motifs (-P-x-x-P-) in 
middle region of HPK1 provide docking sites for many SH3 containing proteins.  So far 
identified HPK1 associated SH3 containing adaptors includes growth factor receptor 
bound 2 (Grb2), Grb2-related adaptor protein (Grap), and Grb2-related adaptor 
downstream of Shc (Gads), HPK1-interacting protein of 55 kDa (HIP-55), B-cell 
associated molecule (Bam32), and Crk family153. Since HPK1 activation involves the 
tyrosine phosphorylation, which serves as additional binding site for SH2 containing 
proteins, such as lymphocyte cytosolic protein 2 (LCP2 or SLP-76) 154. Moreover, HPK1 
can activate some down-stream signaling molecules through its phosphorylation activity. 
In summary, HPK1 have diverse approaches to mediate signal transduction.  
  
After activation of T cell receptor (TCR) by adding anti-TCR antibody to Jurkat cells, the 
HPK1 kinase activity was significantly activated. JNK (c-Jun N-terminal kinase) 
activation was triggered by overexpression of HPK1 in Jurkat cells and further enhanced 
by TCR engagement 155. However, HPK1 kinase dead form M46, where the ATP binding 
site was interrupted, could not activate JNK 35. HPK1 physically bond to and 
phosphorylated MAP3K1 (MEKK1), which is an up-stream activator of JNK 35, 148. 
HPK1 can activate JNK pathway through activating another MAP3K member, MLK-3. 
Interestingly, HPK1 selectively inhibit p38/ERK pathway 35, 148. As a down-stream target 
of MAP kinase, transcription factor AP-1 has its activation be suppressed by HPK1 155. 
HPK1 activation by TCR required the up-stream signaling components, lymphocyte-
specific protein tyrosine kinase (LCK), Zeta-chain-associated protein kinase 70 (ZAP-70), 
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linker for activation of T cells (LAT) and SLP-76 155, 156. A proposed model for HPK1 
activation is that, upon TCR activation, LCK and ZAP-70 is activated. Activated LCK 
and ZAP-70 then phosphorylated the adaptor LAT. Phosphorylated tyrosine on LAT 
provided docking sites for Grb2 or Gads protein, which contains both SH2 and SH3 
domains. Through Grb2/Gads protein, HPK1 and SLP-76 are recruited to adaptor LAT. 
LCK and ZAP-70 phosphorylated some tyrosine sites on HPK1, which ensure HPK1 is 
further activated 154-156. Complete activation of HPK1 involves phosphorylation of 
threonine 165 and serine 171. Serine 171 is phosphorylated by protein kinse D (PKD), 
while phosphorylation of threonine 165 is conducted by HPK1 auto-phosphorylation 157.  
Besides activating JNK pathway, HPK1 can promote T cell apoptosis by inhibiting NF-
κB activity 152. Interestingly, HPK1 could be either a positive or negative regulator of 
NF-κB depending on the T cell status 157. During T cell activation stage, HPK1 is a 
positive regulator of NF-κB. However, in activation-induced cell death (AICD) stage 
which is after T cell expansion, HPK1 turns to a negative regulator of NF-κB. Full length 
HPK1 physically associate with IKK complex component IKKβ.  HPK1 can 
phosphorylate IKKβ and then activate IKK complex. Moreover, HPK1 can stimulate IKK 
complex by phosphorylating adaptor CARMA1 158, which is a member of CARD-
containing membrane-associated guanylate kinase family. CARMA1 is crucial for TCR 
mediated NF-κB activation 159. During T cell AICD stage, HPK1 is cleaved by caspase-3 
160. HPK1-C terminal remains binding to IKKβ. However, TCR induced NF-κB 
activation is blocked 157, 160. HPK1-N terminal is still able to activate JNK pathway to 
promote T cell AICD 152, 161.  
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Role of HPK1 in cancer 
So far there are very few reports on the function of HPK1 in cancer development. HPK1 
may involve tumor progression through regulating immune system or directly 
suppressing cancer cell proliferation.  
 
HPK1-/- bone marrow dendritic cells (BMDCs) turned to be more potent antitumor 
vaccines 150. When tumor lysate-pulsed HPK1-/- BMDCs was injected intratumorally to 
tumor-bearing mice, the tumor was completed eliminated. The control mice injected with 
lysate-pulsed WT BMDCs will reach maximal tumor size by day 50 after vaccination. 
However, mice injected lysate-pulsed HPK1-/- BMDCs remained tumor-free for about 60 
days. Lymphocytes collected from lymph nodes of mice injected with HPK1-/- BMDCs 
obtained extra activity in killing Lewis Lung Carcinoma (LLC) cells 150. In consistent 
with the increased killing potential, T cells collected from HPK1-/- BMDCs vaccinated 
mice had more IFN-γ expression.  
 
As a negative regulator of T cell immune response, HPK1 can also regulate cancer 
progression by directly inhibiting T cell mediated anti-tumor response 162. Non-small cell 
lung cancers (NSCLCs) have poor immunogenic response. One reason is that 
environmental prostaglandin E2 (PGE2) suppresses the anti-tumor immunity. 
Interestingly, PGE2 could not inhibit the IL-2 production on HPK1−/− T cells. The 
proliferation rate of wild type T cells was significantly suppressed by PGE2 compared to 
HPK1−/−  T cells 162. HPK1−/−  T cells were resistant to PGE2 induced apoptosis. In a 
xenograft mouse model for Lewis lung carcinoma, HPK1 knock-out mice barely 
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supported the tumor formation 162. In summary, HPK1 could be a promoting factor of 
non-small cell lung cancer development by suppressing anti-tumor immune response.  
 
On the contrary, HPK1 may function as a suppressor in cancer cells. For example, in 
Hodgkin's lymphoma B cells, HPK1 was required to mediate CD150 caused anti-
proliferation and apoptosis 163. HPK1 was involved in CD150 activated JNK pathway 163. 
Previous research in our lab showed that HPK1 is expressed in normal pancreatic duct 
cells. However, HPK1 showed a progressive loss with the progression of PanIN lesions 
and not detectable in invasive PDAs 164. HPK1 was consistently lost in pancreatic cancer 
cell lines. The loss of HPK1 was due to the increased degradation. Proteosome inhibitor 
MG132 could bring back HPK1 164. The MG132 stabilized HPK1 could reduce 
pancreatic cancer cell proliferation rate and increase protein levels of cyclin-dependent 
kinase inhibitor 1/B (p21/p27), which are inhibitors of cell cycle progression165, 166.  
 
Endocytosis 
 
One major form of protein trafficking is vesicle trafficking. Vesicle trafficking includes 
exocytosis and endocytosis, two processes which are reverse to each other. Endocytosis is 
a process that the cargo collected on the cell surface is compartmented by plasma 
membrane invagination, and vesicle fission from plasma membrane. Endocytosis plays 
important roles in the cell physiology. Endocytosis can allow large molecules that cannot 
permeate the plasma membrane to enter into cells. Endocytosis can also change the lipid 
and protein composition of plasma membrane. Moreover, endocytosis regulates the signal 
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transduction and response 167, 168. In a word, endocytosis provides an important approach 
for cells to communicate with environment. On physiological aspect, endocytosis is 
absolutely required for development, neuron-transmission, immune response, and cellular 
homeostasis 168.  
 
Phagocytosis 
Based on cargo character, endocytosis can be separated into phagocytosis and pinocytosis. 
Phagocytosis is usually triggered when large particles binds to corresponding receptors 
located on plasma membrane 168. The vesicle formed by phagocytosis process 
(phagosome) usually can reach 250 nm in diameter. In protozoon, phagocytosis is a 
common adopted way to obtain nutrition. While in metazoan and higher organism, 
phagocytosis is employed as a defensive trick to clean pathogens or cellular debris by 
some specialized cells like macrophages, and neutrophils 169. Phagocytosis is a strictly 
regulated process 170. When particle binds to the receptor, a signaling pathway is 
activated, and the actin goes to rearrangement until phagosome is formed 170. The 
destination of phagosome is usually ended by merging with lysosome, where the cargo is 
degraded 171. 
 
Pinocytosis 
Pinocytosis, also called fluid-phase endocytosis, is a receptor independent and non-
selectable endocytic process 172. Pinocytosis starts with a clathrin coated pit, and end with 
a clathrin coated vesicle. During the pinocytosis, a bit of fluid from cell outside and its 
dissolved molecules is compartmented and get entry into cell 167. The diameter of 
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endosome formed through pinocytosis is usually less than 150 nm. Pinocytosis is a 
constitutively happened process in almost all cells, and extremely active in epithelial cell 
of intestinal, blood capillary, and kidney tubule173.  
 
Based on molecular machinery involved in the endocytosis, the endocytosis pathway can 
be divided into clathrin-mediated endocytosis, caveolin-mediated endocytosis, and actin-
mediated endocytosis. 
 
Clathrin-mediated endocytosis 
Clathrin is a cytosolic protein that can bind to the outer surface of transport vesicles. 
Formation of clathrin-coated vesicles (CCVs) requires Clathrin. Clathrin contains 1 
heavy chain (180KD) and 2 light chian (33, 36KD). The basic assembly unit of clathrin is 
triskelion which is composed of 3 heavy chains and 3 light chains 174. Clathrin triskelion 
can self-assemble to a ball-shaped lattice. Clathrin alone can assemble a cage in vitro but 
not in vivo, suggesting the machinery for clathrin-mediated endocytosis requires other 
proteins 174.  
 
A normal clathrin-coated vesicle structure needs adaptor proteins (AP) and accessory 
proteins 175. Plasma membrane-associated AP-2 complex is composed of 4 highly 
conserved subunits. AP-2 complex was located between the clathrin lattice and 
membrane, which provide docking sites for clathrin on vesicles. Clathrin alone can form 
coated vesicles in vitro with large variation in size. However, when adaptor protein was 
added, the size of clathrin coated vesicle was unified, indicating that AP-2 complex can 
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help to organize clathrin lattice 176.  In another end, adaptor proteins can recognize the 
cytosolic part of cargo, like receptors. Adaptor proteins can facilitate cargo clustering 174.   
 
One crucial step for calthrin-mediated endocytosis is to cut off the clathrin coated 
vesicles from plasma membrane. A large GTPase, dynamin, fulfill the above duty.  
Dynamin can be docked to plasma membrane by recognizing phosphatidylinositol 4,5-
bisphosphate (PIP2). The dynamin, which is recruited and enriched by some accessory 
proteins, can polymerize around the neck of clathrin coated vesicles. Finally, through the 
GTP hydrolysis, Dynamin scissor the clathrin coated vesicles off the plasma membrane 
177, 178. The clathrin coated vesicles, freed from plasma membrane, will be uncoated and 
finally fuse with early endosome 177.  
 
Caveolin-mediated endocytosis 
Almost all mammalian cells have flask-shaped invaginations, which are called caveolae. 
Caveolae are covered with caveolins and other coat proteins which are not found in 
clathrin coated vesicles 179. Usually, caveolae is formed in lipid raft which has enriched 
cholesterol and sphingolipid. The caveolae genesis sites on plasma membrane can be 
explained by its coat protein caveolins which can recognize cholesretol. Caveolins are 
acetylated membrane protein with molecular between 22-24 KD 179. Caveolins can self-
asemble to a cage which holds the membrane invaginations. Knocking-out the caveolin-1 
in mouse will damage the genesis of caveolin-mediated endocytosis 180, 181.  
 
27 
 
One of other important components of caveolae is Cavin protein. Cavins are small 
proteins with molecular weight between 10-15 KD. Cavin-1 silencing reduced the total 
amount of caveolae, and the size of caveolin 1 polymers 179, 182. Cavins can bind to 
Caveolin and physically locate the outer side of Caveolin cage 179.  
 
Caveolin-mediated endocytosis is a strictly regulated process and involves a serie of 
signaling cascade 183, 184, 185. For example, when SV40 virus binds to its receptor, a burst 
of tyrosine kinase activity was observed. Under signal stimulus, the actin around caveolae 
start to rearrange 179, 185. Finally the dynamin was recruited and the caveolae was scissor 
off from plasma membrane. The freed caveolae will fuse with other endosomes, such as 
early endosomes 179, 185. Caveolin-mediated endocytosis is expected to participate in 
many physiological behaviors, like signaling transduction, cargo transport, and adjust the 
plasma membrane lipid composition 186, 187.  
 
Receptor-mediated endocytosis 
The receptors on cell plasma membrane have an important role in endocytosis. Receptor 
mediated endocytosis can be clathrain, caveolin-dependent, or independent 188, 189. 
Receptor mediated endocytosis allow cells to selectively internalize some nutrient 
components, like low-density lipoprotein (LDL), transferrin 189, 190. Accompanied with 
the clearance of receptor-bound ligands, the recycled receptor will be prepared to respond 
another around of stimuli 188, 189. Recently, the receptor mediated endocytosis had been 
explored for its potential in drug delivery. For example, therapeutic nanoparticles can be 
conjugated with ligands and its internalization by targeted cells will be increased 191.   
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Though all receptors have some base level of intrinsic turnover through endocytosis 
pathway, the receptor internalization will be dramatically induced after ligand binding 189. 
Using receptor EGFR as an example, without EGF binding, the constitutive 
internalization is relatively slow (t1/2 20–30 min). However; the internalized the empty 
EGFR are recycled back to plasma membrane very quickly (t1/2 5 min) 192. In contrast, 
after EGF binding, EGFR internalization rate is increased dramatically (t1/2 4 min), and 
only a partial of EGFR recycle back to the plasma membrane. Moreover, the recycling 
rate of EGF bound EGFR is expected to be slower than the empty EGFR 192, 193. A 
significant fraction of ligand bound EGFR will go through endosomal sorting 192. The 
most frequently induced type of EGFR endocytosis by EGF is clathrin-mediated 
endocytosis. Nevertheless, in different cell type or physiological condition, EGFR may 
go through Caveolin-dependent, or other clathrin-independent endocytosis193.  
 
Receptor-mediated endocytosis is a process highly controlled by the receptor activated 
signaling. When EGF binds to EGFR, EGFR start to dimerize and the tyrosine activity is 
activated. The phosphor-Tyrosine sites on EGFR provide some docking sites for some 
adaptors, like Grb2, which can further recruit down-stream signaling molecular, or 
molecular regulating the endocytosis pathway 194. Ubiquitin E3 ligase Cbl, which is 
recruited by Grb2, will give EGFR a tag, which can be recognized by other endocytosis 
related adaptor, such as Hrs. and lead to endosomal sorting or degradation in lysosome 194, 
195. In addition, some signaling molecular which is not directly activated by receptor itself 
will help to regulate receptor-mediated endocytosis. For example, protein kinase C (PKC) 
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can phosphorylate Thr654 site on EGFR, and cause decreased EGF endocytosis 196. 
Mitogen-activated protein kinase (MAPK)/p38 can even trigger the endocytosis of 
unoccupied EGFR, after phosphorylating serines in EGFR C-terminal domain 197, 198.   
 
Endocytosis organelles 
On above sections, we described how endocytic vesicles are generated. In this section, we 
will introduce the common endocytosis organelles that participate in the endosomal 
sorting. Based on the biochemical character and functions, endocytosis organelles can be 
divided into early endosome (EE), multi-vesicular body (MVB)/late endosome (LE), and 
lysosome. The cargo in endocytic vesicle may selectively go through some, or all of 
above endocytic organelles.     
 
Early endosome 
Early endosome is irregular a membrane compartment containing some large vesicles 
(~400 nm diameter) and tubules (~60 nm diameter) 199. The distinct morphological 
structures in early endosome are expected to be required for separating cargo in different 
space 199. The cargo for returning back to plasma membrane is usually clustered in 
tubules, whereas, the cargo targeted to degradation will be collected in large vesicles 200.  
As a common sorting endosome for nascent endocytic vesicle to fuse with, early 
endosome is a very dynamic structure 199, 200. The biogenesis of early endosome is still 
elusive. One possibility is that early endosome creates from the vesicles coming off the 
plasma membrane. Another possibility is that the vesicles budded from Golgi bodies give 
rise early endosome. On a giving early endosome, it may be a fusion product of several 
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vesicles from different sources. In matching with the sorting function, early endosome is 
featured with a mild low pH micro-environment (~pH6.3) 201. In this low pH solvent, 
ligand EGF is able to release from receptor EGFR 201. Early endosome specific GTPase 
Rab5 carries out crucial role in vesicle motility, budding and fusion. Except Rab5, the 
Rab5 effector, early endosomal antigen-1 (EEA1) can also serve as early endosome 
marker 202.        
 
Multivescicular Body (MVB)/late endosomes 
A mature late endosome is also named multivescicular body (MVB). The morphology of 
MVB can be described as a spherical membrane compartment with multiple intralumenal 
vesicles (ILVs) 203, 204. MVB is generally considered as a product of early endosome 
maturation 203, 204. Right after early endosome formation, some part of cargo will recycle 
back to cellular plasma membrane, while left cargos will be sorted in late endosome and 
finally delivered to lysosome. Early endosome maturation process involves removal of 
recycling related proteins and integration of proteins directed to fusion with lysosome 203, 
204. Small GTPase Rab protein replacement is one of symbolic events of endosome 
maturation. During maturation Rab5 is replaced by Rab7 205. One key behavior of early 
endosome maturation is the formation of ILVs, which can be observed as small vesicles 
inside the endosome 203, 204. The mechanism of ILV formation is complicated and not 
univocal 203, 204. Plasma membrane inward budding on endosome may be an automatic 
behavior of membrane with given lipid composition 206. Endosomal sorting complex 
required for transport (ESCRT) played roles in ILV formation and cargo sorting 206-208. 
As the question of which proteins should be sorted in ILVs, ubiquitination on trans-
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membrane proteins provides a recognition site for ESCRT machinery 206-208. After MVB 
formation, the contained cargo will finally be delivered to lysosome by fusing together.           
 
Lysosome 
Lysosome is a digestive organelle in mammalian cells. In consistent with its protein 
degradation function, lysosome is filled with digestive enzymes, acid hydrolases 209. 
There are about 50 acid hydrolases, which are specific to different protein substrates 209. 
For the optimal activity of acid hydrolases, a favorable acidic pH(4.5~5.0) is maintained 
in lysosome by a group of lysosomal membrane proteins (LMPs) 209. So far around 40 
human disorders is associated with lysosomal enzyme deficiencies 210. Lysosome 
disorders have been found in cancer. For example, some of lysosomal cysteine 
proteinases (Cats) were found to be overexpressed in breast cancer 211.  
 
Aberrant endocytosis pathways in cancer  
Accumulated evidences indicated that endocytosis pathways participate in cancer 
progression 212. The first step of metastasis is cancer cell dissolute from cell-cell junctions, 
which are maintained by endocytic-exocytic cycles 212, 213. In case of cancer, some 
oncogenic signaling will break this endocytic-exocytic balance. Overexpression of 
CDC42, a small GTPase, promoted the progression of testicular 214. CDC42-GTP can 
lead tight junction proteins to lysosome for degradation 215. Some oncogenic RTKs can 
phosphorylate E-cadherin, which is major component of adherent junctions. The 
phosphorylated E-cadherin recruits E3 ubiquitin ligase, Hakai. After ubiquitination, the 
internalization and lysosomal degradation of E-cadherin is dramatically increased 216. E3 
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ubiquitin ligase Cbl is crucial for down regulating receptor tyrosine kinase through 
endocytosis pathway. However, in cancer, the connection between Cbl and RTKs is 
somehow disrupted by mutations happened on either Cbl or RTKs 217-219, 220. The 
aberrations of components in endocytosis pathway were also frequently discovered in 
cancer 212. Caveolin 1, an essential factor for caveolin-mediated endocytosis, is found to 
be involved in the progression of several types of cancer. Amplification of Caveolin 1 
gene was found in aggressive breast cancer. Caveolin 1 is a marker for poor prognosis in 
gastrointestinal cancer221-223. VPS37A, an ESRT-I protein, is down regulated in 
hepatocellular carcinoma (HCC). Knockdown of VPS37A stabilized EGFR expression 
and promoted HCC cell invasion 224. More and more endocytosis aberrations have been 
reported in literatures. In summary, cancer progression needs the participation of 
endocytosis pathway. On other hand, the alteration of endocytosis pathway contributes to 
cancer progression. 
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Specific aims 
Pancreatic cancer is one of the most malignant diseases. In USA, Pancreatic cancer 
causes approximately 36,800 deaths each year 1-3. Overall 5 year survival rate of 
pancreatic cancer patients is less than 5% 1-3 . The absence of early diagnostic markers 
and effective treatments accounts for the high mortality 4, 5. Exploring potential 
therapeutic targets is highly demanded. Though Ras mutation is considered as major 
driving factor of pancreatic cancer development 26, 62, the molecular mechanisms leading 
to  pancreatic cancer are unclear.  
 
Oncogenic receptor tyrosine kinases (RTKs) play important roles in cancer development 
115. Axl was firstly identified by a DNA transfection-tumorigenesis assay with the DNA 
from chronic myelogenous leukemia (CML) patients. The sequence analysis revealed that 
it has one typical tyrosine kinase domain in the cytoplasmic part, and two immunoglobin-
like and two fibronectin like repeats juxtaposed in the extra-cellular domain which 
provides a bind site for ligand growth arrest specific factor 6 (Gas6), or Pro S. As a 
member of the receptor tyrosine kinase (RTK) family, Axl was tested to have cell 
transforming activities just like some other oncogenetic RTK members did. So far, the 
accumulating data of the Gas6-Axl pathway investigated with colon cancer, lung cancer, 
thyroid carcinomas, breast cancer, and glioma revealed that the elevated Axl closely 
associated with the tumor malignancy. Further experiments through manipulating Axl 
expression levels suggested that Axl can contribute to cell proliferation, anti-apoptosis 
migration, and invasion. However, the knowledge of Gas6/Axl pathway in pancreatic 
cancer is still a missing part. 
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Furthermore, how Axl protein levels are regulated in cancer is unknown. Hematopoietic 
progenitor kinase (HPK1) functions as tumor suppressor in pancreatic cancer. 
Interestingly, HPK1 protein is lost in more than 95% of pancreatic ductal 
adenocarcinoma (PDA). The molecular mechanism of how HPK1 suppress cancer 
development is yet to be investigated. HIP-55 constitutively binds to HPK1. HIP-55 is 
involved in the receptor down regulation through endocytosis pathway 225, 226. HPK1 
knockdown B- lymphoma cell displayed a significant less internalization rate of IgM 
which binds to B cell receptor (BCR) 227. Our lab’s research showed that Axl is a binding 
partner of HPK1. The physical connection between HPK1 and Axl provides a probability 
that Axl protein levels can be regulated by HPK1 through endocytosis pathway. For the 
purpose to address above questions, on the first step, I hypothesized that Axl has 
oncogenic functions on pancreatic ductal carcinoma (PDA) progression, and Axl protein 
levels is regulated by HPK1 through endocytosis pathway. To test above hypothesis, the 
following specific aims were developed.  
 
1) To determine the oncogenic role of Axl in PDA progression 
 
2) To investigate the role of HPK1 in Axl degradation through endocytosis pathway
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CHAPTER 2: Materials and methods 
 
Tissue Microarray 
The pancreatic samples were collected from 54 patients who did not receive any cancer 
therapy. The tissue was fixed with formalin and embedded in paraffin. Two cores each of 
tumor and non-neoplastic pancreatic tissue were punched and aligned on a slide using a 
tissue microarrayer (Beecher Instruments, Sun Prairie, WI). More details about tissue 
array construct can refer to pervious paper published by our lab 228. The sample collection 
and following study was approved by the institutional review board of the M. D. 
Anderson Cancer Center 229. 
 
Immunohistochemistry 
The formalin-fixed, paraffin-embedded tissue was dried at 58°C for 1 hour in an oven, 
and deparaffinized by soaking slides in xylene, ethonal, and finally distilled water. 
Antigen was retrieved by steaming slides in target retrieval solution, 10 mM citrate buffer 
(Dako Inc. Cat# S1699) for 35 minutes. After slowly cooling down slides together with 
the target retrieval solution under room temperature, the slides was washed by PBS buffer 
for 3 times, 10 minutes per time, and endogenous peroxidase was blocked with 3% 
hydrogen peroxide solution in PBS buffer for 20 minutes. The leftover hydrogen 
peroxide was cleaned with PBS for 3 times as above. The tissue was blocked with 2.5% 
normal serum for 30 minutes to reduce nonspecific probing. Here, the second antibody 
was from goat. So, the normal serum should be normal goat serum. For probing Axl 
antigen, anti-Axl antibody (Rabbit source, Abcam Inc. Cat# 37861) was diluted 1:50 
36 
 
normal serum blocking solution, and coved the tissue for overnight at 4°C. After washing 
out the primary antibody with PBS buffer, the sections were incubated with biotinylated 
secondary anti-rabbit antibody (Vector Laboratories, Burlingame, CA) for 1 hour at room 
temperature, washed with PBS for 3 times as above. The section was labeled with avidin-
biotin-peroxidase complex (ABC kit, Vector Laboratories, Burlingame, CA. Cat# PK-
4001) for 30 minutes, and washed with PBS.  To visualize the immunostaining, the 
sections were incubated with fresh DAB solution (Dako Inc. Cat# K3468) and monitored 
under microscope. After ideal signal was observed, the reaction was stopped by rinsing 
with water. Nuclear counterstain was performed by immersing slides in Mayer’s 
Hematoxylin, and bluing reagent (Richard-Allan Scientific Co. Cat# 7301). Finally, 
slides were covered with coverslip using mount medium (Vector Laboratories, 
Burlingame, CA. Cat# H-5501) 230, 231.  The completed Axl staining would be subjected 
to following analysis 229.  
 
Quantification of the Axl Expression in PDA samples  
After immunohistochemistry staining of slide with pancreatic ductal adenocarcinoma 
tissue microarray, the slide was scanned and analyzed with Ariol 2.1 scanner and digital 
imaging instrument (Applied Imaging, San Jose, CA). The duct cells in both tumor and 
benign tissue were exclusively marked using a hand-draw tool. The intensity and 
percentage of Axl staining in marked cells was combined to give a score. Based on Axl 
staining score, the PDA specimens were categorized into 2 groups: Axl high (score 
≥7.56), and Axl low (score < 7.56).  Collected raw data were subjected to statistical 
analysis 229.   
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Statistical analysis 
Whether there is a significant difference between Axl high and low group was tested by 
Fisher exact test. Overall survival rate and recurrence-free survival time for each group 
were plotted using the Kaplan-Meier method 232. The statistical significance of difference 
between survival curves was evaluated by log-rank test. Overall survival time was 
counted from the date of diagnosis to date of death, or to the date of last follow-up. 
Recurrence-free survival time was counted from the surgery date to the date of first 
recurrence. All patients’ data was obtained from MD Anderson institutional pancreatic 
cancer data base, which is under review of the US Social Security Index. Univariate Cox 
regression analysis was adopted to test prognostic significance of clinical and pathologic 
characteristics. The 2-sided significance level of P < .05 was set for all statistical analyses 
229. 
 
Cell culture 
Human pancreatic cancer cell lines, Panc-1, Capan-1, BxPC-3, and ASPC-1 were 
purchased from American Type Culture Collection (ATCC. Manassas, VA).  The 
CFPAC-1, Panc-48, Panc-3, Capan-2, Panc-28, Hs766T, MIA PaCa-2, and L3.6pl 
pancreatic cancer cells were generously provided by Dr. Paul Chiao (The University of 
Texas M. D. Anderson Cancer Center). All cell lines were cultured in either Dulbecco’s 
modified Eagle’s medium (DMEM) or RPMI-1640 medium supplemented with 10% fetal 
bovine serum (Hyclone Inc. Cat#30014.03). The immortalized normal human pancreatic 
ductal epithelial (HPDE) cell line was kindly provided by Dr. Ming-Sound Tsao (Ontario 
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Cancer Institute, Toronto, ON, Canada). HPDE cells were cultured in Keratinocyte-SFM 
medium (GIBCO Inc. Cat#10724 ) supplemented with a kit (GIBCO Inc. Cat#37000) 
containing recombinant human EGF and bovine pituitary extract. All cells were 
maintained in a humidified incubator (Forma Scientific Co.) at 37 °C with 5% CO2.   
 
Western blotting assay and antibodies 
The cell lysates were prepared with the lysis buffer containing 20 mM HEPES (pH7.4), 
150 mM NaCl, 1% Triton X-100 (V/V), 10% glycerol (V/V), 50mM β-glycerophosphate, 
2mM ethylenediaminetetraacetic acid (EDTA), 1mM phenylmethylsulfonyl fluoride 
(PMSF), 1mM Na3VO4, 10μg/mL leupetin, 1μg/mL pepstatin A, and 2.8μg/mL 
Aprotinin. After setting lysis on ice for 30 minutes, the lysates were clarified by 
centrifugation (2, 0817 x g for 15 minutes at 4oC). The protein concentration of cell 
lysates is measured by the Bradford assay (Bio-rad Co.). Protein were separated by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then 
transferred to polyvinylidene difluoride (PVDF) membrane. The blot was blocked with 
either 5% none fat milk in PBST (0.05% Tween-20) or 5% BSA in TBST (for 
phosphorylated protein). Then primary antibodies diluted in blocking buffer were used to 
probe target proteins on blot.  Based on the animal source of primary antibody, proper 
secondary body, labeled with horseradish peroxidase, was chosen to hybridize with 
primary antibody. After detection with enhanced chemiluminescence (ECL, GE Health 
Co.), the PVDF membranes were exposed to x-ray film. The primary antibodies used 
here are anti-Axl (Goat, Cat# SC-1096, Santa Cruz Co.), anti-Gas6 (Goat, Cat# SC-1936, 
Santa Cruz Co.) anti-Actin (Goat, Cat# SC-1616, Santa Cruz Co.), anti-EGFR (Rabbit, 
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Cat# SC-03, Santa Cruz Co.), anti-PARP (Rabbit, Cat# SC-7150, Santa Cruz Co.), anti-p-
AktSer473 (Rabbit, Cat#9271, Cell Signaling Co.), anti-Akt (Rabbit, Cat#9272, Cell 
Signaling Co.), anti-IGFBP6 (Rabbit, Cat# SC-13094, Santa Cruz Co.), and anti-MMP-2 
(Mouse, Cat#IM33L, Oncogene Co.) 229.  
 
Stably silencing Axl expression in PDA cell lines  
A set of lenti-virus-based Axl shRNA expression plasmids (5 constructs), pLKO.1-shAxl, 
were purchased from were purchased from Open Biosystm Co. (AL, U.S.,). Each plasmid 
contains a unique hairpin sequence targeting to different region of Axl cDNA (Gene 
Bank entry, BC03229). The lenti-virus packaging plasmids psPAX2 and PMD2.G, and 
empty vector pLKO.1 were courtesy of Dr. Craig Logsdon lab (University of Texas, MD 
Anderson Cancer Center). The viral particles were obtained by co-transfecting above 
packaging plasmids and shRNA expression plasmid into HEK 293T cells. More details 
about lenti-virus packaging and clarifying could refer to previous published protocol233. 
After infecting Panc-1 and Panc-28 cells with viral particles for 24 hours, the cells were 
subjected to selecting culture with the conditioned medium containing puromycin at 
2μg/mL for Panc-1 cell line and 1μg /mL for Panc-28 cell line. Then single colonies were 
picked for further selection and amplification. The Axl-silenced colonies were screened 
by Western blotting assay using parental cells as control. Here, Axl shRNAs with 
sequence 5’-gcggtctgcatgaaggaatttctcgagaaattccttcatgcagaccgc-3’ (Cat# 
TRCN0000001038), and 5’-cgaaatcctctatgtcaacatctcgagatgttgacatagaggatttcg-3’ (Cat# 
TRCN0000001040) gave most efficient silencing. Multiple colonies of each stable cell 
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line made with above shRNAs were used in following experiments. Stable cell lines 
made with empty vector pLKO.1 served as vector alone control.   
 
In vitro migration assay 
The Costar 24-transwell (Becton Dickinson Labware Inc. Bedford, MA) was used in the 
migration assay. The lower compartment containing 0.6 mL of 2% FBS DMEM served 
as chemoattractant. 3x104 cells from each cell line were seeded with 0.6 mL of serum 
free medium in upper chambers. After 8 hours of migration assay. The filter was washed 
with PBS, cleansed with a cotton swap, and then fixed with methonal. To visualize the 
cells on filter, staining with hematoxylin was performed. Finally, the filter was cut off the 
chambers and mounted on a slide. Cells on each filter were counted under assistance of 
an Olympus BX40 microscope. The experiments were repeated 3 times. Differences 
between Panc-28, pLKO.1-Panc-28, and Sh-Axl-Panc-28 cell lines were compared and 
analyzed by student’s t test.   
 
In vitro chemoinvasion assay 
24-well Biocat matrigel invasion chamber (Becton Dickinson Labware Inc. Bedford, MA) 
was used here for chemoinvasion assay 229. 0.75mL of DMEM with 10% FBS located in 
the lower compartment served as chemoattractant. 2.5x104 cells from each cell line in 
experiment were seeded in the upper compartment, which contained 0.5mL of serum-free 
medium. Experimental samples were set in a triplicate manner. After 24 hours of 
incubation in a humidified incubator with 5% CO2 at 37°C, the cells passed the 
membrane were fixed by methanol and stained with hematoxylin. The cell numbers in 5 
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predetermined fields on each membrane were counted under an Olympus BX40 
microscope. The statistical differences in invasion rate between Panc-28, pLKO.1.1-
Panc-28, and shAxl-Panc-28s cell lines were measured by students’ t test.  
 
Detection of secreted matrix metalloproteinase-2 (MMP-2) 
PDA cells in test were grown to 80% confluence. The medium were changed to serum 
free medium and kept growing for another 24 hours. Then the serum free medium was 
collected. The secreted proteins were concentrated through Microcon Centrifugal Filter 
Device (Millipore Co. Cat#42410) as instructed by manual. Detection of secreted MMP-2 
will follow a standard Western blotting procedure. Western blotting detection on another 
secreted protein, insulin-like growth factor binding protein 6 (IGFBP6) 234, 235, served as a 
loading control of total amount protein.        
 
Treating cells with Gamma-irradiation 
The effects of Axl silencing on cell response to Gamma-irradiation was measured by 
PARP cleavage assay. The number of cells in apoptosis was also reflected by counting 
the cells in sub-G1 stage. The irradiation source was provided by a cesium 137 (Model E-
0103; US Nuclear Corp., Burbank, CA). One day before irradiation, 1x106 of cells was 
seeded into Ф10cm culture dish, which will give about 50% confluence of cell density 
right before irradiation. The irradiation dose for Panc-28 and Panc-1 cell series are 20 and 
30Gy respectively. After irradiation, the cells will keep grow in incubator for another 48 
hours. Then the cells were collected for either Western blotting assay to detect PARP 
cleavage, or added with hypotonic solution (0.1% sodium citrate, 0.1% Triton X-100, 100 
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µg/mL of RNase, and 50 µg/mL of  propidium iodide). The propidium iodide stained 
cells were be sorted through a flow-cytometer (Beckman Coulter Inc., Brea, CA) based 
on the amount of DNA in cells. The ratio of cells in sub-G1 were be calculated, and 
compared between parental, vector alone, and Axl silenced cells.   
 
Quantitative real time PCR (QRT-PCR) 
The total RNA from HPDE, and pancreatic cancer cell lines were extracted by TRIzol 
(Invitrogen Inc.) method 236. After cells were cultured in Ф10cm plates to 80% 
confluence, the medium were removed; then 1mL of TRIzol reagent was added on cells. 
Setting plates under room temperature for 5 minutes, and pipetting lysates for several 
times, so the nucleo-protein could be disassociated from RNA completely.  After 
collecting the lysate into a 1.5 mL eppendorf tube, 200 µL of chloroform was added. 
Samples were vortexed briefly and incubated at room temperature for 5 minutes. To 
separating aqueous phase, samples were centrifuged at maximal speed (>12,000g) with a 
laptop centrifuge for 15 minutes under 4°C. The upper aqueous phase, which contained 
RNA, was carefully transferred to a new eppendorf tube. To precipitate RNA, equal 
volume of isopropanol was added. After centrifuging tubes at maximal speed (>12,000g) 
for 30 minutes under 4°C, the supernatant was removed. RNA pellets were washed with 
75% ethonal which was prepared with DEPC-water. Finally, RNA pellets were dissolved 
in certain amount of DEPC-water. RNA concentration was measured with Nano-dropper.  
 
For cDNA synthesis, a reverse transcription system (Promega Co. Cat#A3500) was used 
237. Following the manual provided by the company, the random primer was chosen here. 
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The reaction condition was 42°C for half hour. Finally the reaction was stopped by 
heating samples at 95°C for 5 minutes. The final 20 µL of product were diluted by adding 
180 µL of autoclaved water. In each PCR reaction with volume of 20uL, 5 µL of 
template was added. The products of quantitative real time-PCR were labeled with cyber 
green (Bio-Rad Co.). Axl primers used here were 5’-GGTGGCTGTGAAGACGATGA-
3’ (Forward), and 5’-CTCAGATACTCCATGCCACT-3’ (Reverse). RT-PCR was 
performed using a thermal cycler (Bio-Rad Laboratories, Inc.) for 40 cycles consisting of  
30s at 95°C (denaturation), 30s at 58°C (annealing), and 45s at 72°C (extension). Each 
sample test was triplicated. The mean values of cycle numbers at thresh holder were 
obtained. The RT-PCR performed with primers (forward, 5′-
AAGGAGAGAAGGATATTCCTGGAC-3′; reverse, 5′-
AGAGAGATTGAAAAGTTTGCGGAT-3′) specific to Ribosomal Protein Small 
Subunit 6 (RPS6) served as internal control, reflecting the total amount of cDNA in 
reaction 164.  
 
Measuring NF-κB activity by luciferase reporter assay 
In order to measure NF-κB activity, the NF-kB-Luc-reporter with a firefly luciferase 
reporter gene was transfected into PDA cells using FuGENE HD transfection reagent 
(Roche Co. Cat#04-709-705). Plasmids of NF-kB-Luc-reporter were kindly provided by 
Dr. Logsdon lab.  Transfection procedure followed the standard protocol as described in 
product manual. In each well of 6-well plate, 2µg of NF-kB-Luc-reporter plasmids were 
transfected. After 48 hours of transfection, substrate D-luciferin was added to cells with 
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final concentration of 150μg/mL. The intensity of luminescence was recorded by IVIS 
bioluminescence system (Xenogen Co.) 238.   
 
Antibody array 
An antibody array membrane, with 400 different immobilized antibodies, was purchased 
from Hypromatrix Company. The Flag-HPK1-Panc-1 cells were cultured in 2 of 15cm 
culture dish. Next day, after cell attaching the dish bottom, 1 uM of proteasome inhibitor 
MG132 was added to the culture medium and cultured cells for another 36 hours. The 
cell lysate was prepared.  The protein concentration was measured by bio-rad protein 
assay. The expression of Flag-HPK1 stabilized by MG132 was tested by Western blotting. 
At the beginning, the antibody membrane was blocked in 5% non-fat milk in TBST(150 
mM NaCl, 25 mM Tris, 0.05% Tween-20, pH 7.5) at room temperature with gentle 
shaking for 1 hour. Then around 5 mg of whole cell lysate was incubated with antibody 
membrane at 4°C for overnight. After washing with TBST for 3 times, the membrane 
associated HPK1 was probed with anti-Flag antibody, which is conjugated with HRP 
complex.    
 
Transfection 
In 6-well culture plates, 6X105 of HEK293T cells were seeded. After overnight growth, 
the cell density reached to around 80% confluence. 4 hours before transfection, the 
culture medium (DMEM+ 10%FBS) were changed to fresh medium. Transfection was 
completed with Calcium Phosphate transfection kit (Millipore Co. Cat#S-001) 239. The 
designed plasmids were pipetted to 5 mL round-bottom tubes (Becton Dickinson Co. 
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Cat#352058). For scale of 10 transfections, solution A was prepared by mixing 200µL of 
10XHBS, 1.75mL of sterilized ddH2O, 30µL of NaOH, and 20µL of phosphate solution; 
Solution B was prepared by mixing 200µL of  Calcium solution, and 1.8mL of sterilized 
ddH2O. In each transfection, 100µL of solution A was added to mix with plasmid. Then 
100µL of solution B was dropped into the mixture of solution A and plasmids, 
accompanied with vigorous vortex. After setting tubes in hood for 30 minutes, the 
mixture of plasmid and solution A/B was dropped into planned well of culture plates. 
After transfection of 12 to 16 hours, the culture medium was changed to fresh medium. 
Upon the experiment requirements, HEK293T with transfected plasmids continued 
growing for another 16 to 24 hours. At the end, cells were collected for following 
experiments.  
 
Co-immunoprecipitation 
Cell lysates used for co-immunoprecipitation were prepared as the same way used for 
Western blotting. In each co-immunoprecipitation, 200 to 500µg of total protein were 
mixed with 2µg of either antibody, or normal serum IgG. Additional lysis buffer was 
added to reach total volume of 300 to 500µL.  After 3 hours of incubation at 4°C with 
gentle rotating. 20µL (before washing off slurry) of protein A or G beads (based on 
animal source or subtype of antibody) was added to precipitate the antibody-protein 
complex. The binding of beads with antibody-protein complex was completed by gently 
rotating tubes under 4°C for 1 to 2 hours.  Beads were collected by spinning samples at 
8,000 rpm for 1 min under 4°C.  The non-specific associated proteins were washed with 
500µL of lysis buffer for 2 times. The antibody-protein complex was eluted by adding 
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reducing protein loading buffer and boiling samples for 5 minutes. More technical details 
of co-immunoprecipitation could refer to previous published protocols 240 241. Co-
immunoprecipitated proteins were detected by regular Western blotting. To 
immunoprecipitate the flag tagged protein, M2 beads (Sigma Co. Cat#2426), which has 
conjugated anti-flag antibody, was adopted. The antibodies used for co-
immunoprecipitation were anti-Axl (Goat, Cat# SC-1096, Santa Cruz Co.), anti-HPK1 
(Goat, Cat# SC-6231, Santa Cruz Co.), anti-EGFR (Rabbit, Cat# SC-03, Santa Cruz Co.), 
anti-Dynamin (Rabbit, Cat#SC-11362, Santa Cruz Co.), and anti-P-Thr (Mouse, Cat# 
SC-1096, Santa Cruz Co.).  
 
In vitro kinase assay of HPK1 
10µg of pCI-Flag-HPK1, pCI-Flag-M46 (kinase dead form of HPK1), pCDNA-Flag-
HPK1-KD, pCDNA-Flag-HPK1-CD, and pCDNA-Flag-Axl expression plasmid was 
transfected individually to HEK 293T cells, which was cultured in Ф 10cm plates, using 
Calcium Phosphate transfection kit. After 36 hours of transfection, cells were collected 
and lysised in lysis buffer (20mM of HEPES, pH7.4, 20mM of EGTA, 50mM of β-
glycerophosphate, 1% Triton X-100, 10% Glycerol, 150mM of NaCl), which was added 
with fresh protease inhibitors. HPK1 complex, and its substrate Axl complex were 
immunoprecipitated by using M2-beads. Immunoprecipitated complexes were 
sequentially washed with 1mL of lysis buffer for 2 times, LiCl buffer (500mM of LiCl, 
100mM of Tris, pH7.6, 0.1% of Triton X-100) for 2 times, and kinase buffer (20mM of 
Mops, pH7.2, 2mM of EGTA, 10mM of MgCl2, 0.1% Triton X-100) for another 2 times. 
Immunoprecipitated HPK1 complex and substrate Axl complex were mixed together with 
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35µL of kinase buffer which contained 50µM of cold ATP and 10µCi of [γ32P]ATP. 
Kinase reaction was completed by incubation for 30 minutes at 30°C. Kinase reaction 
was stopped by adding Laemmli buffer and boiling for 5 minutes. After cooling down 
and briefly spinning the samples, boiled supernatants were loaded on a 10% SDS-
polyacrylamide gel.  When finished running, gel was exposed to an X-ray film. More 
details of in vitro HPK1 kinase assay can refer to previous published paper by Dr. Tan 
lab 151, 242. To test whether Dynamin was also a substrate of HPK1, endogenous Dynamin 
from HEK293T cells was immunprecipitated by anti-dynamin II antibody (Rabbit, 
Cat#SC-6400, Santa Cruz Co.). 
 
Measurement of protein half-life 
Protein translation was inhibited by adding translation inhibitor cycloheximide (CHX) to 
final concentration of 100µg/mL. CHX was added at different time points from 0 to 6 
hours. Protein Axl in measurement was detected by Western blotting. The intensity of 
Western blotting bands was quantified by software Image J. The ratio between Axl and 
loading control actin was calculated. The average value after 3 repeats was calculated and 
plotted in a 2 axis figure.  
 
Construct of HPK1 inducible expression stable cell line 
To establish HPK1 inducible expression system, a Lenti-X™ Tet-On® Advanced 
Inducible Expression System (Clontech Laboratories, Inc.) was adopted.  First step, 
pLVX-Tet-On Advanced vector, which constitutively express a tetracycline-controlled 
transactivator, rtTA-Advanced, was introduced to Panc-1 cells. The lenti virus based 
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pLVX-Tet-On Advanced vector was packaged to lenti virus by co-transfecting with 
packaging plasmids, Lenti-X HTX Packaging Mix (Cat#632156), into 293T cells. The 
medium containing lenti-viral particles were collected to infect Panc-1 cells. Since 
pLVX-Tet-On Advanced vector has a Neo resistant gene, which can be used to select 
stable Panc-1 cell lines. Here, single colonies of pLVX-Tet-On-Panc-1 stable cell lines 
were selected under condition medium containing 400µg/mL of G418 (neomycin 
analogue). The expression levels of transactivatior rtTA-Advanced in each stable colony 
were screened by Western blotting using antibody (Cat.Nos. 631108) specific to TetR 
protein. The transcriptional activity of rtTA-Advanced in Panc-1 cells was confirmed by 
temporary transfecting pLVX-Tight-Puro-Luc plasmid and following luciferase assay. 
Protein rtTA-Advanced has transcriptional activity only when tetracycline or doxycycline 
(tetracycline analogue) was present. Second step, lenti virus based pLVX-Tight-Puro was 
used to construct HPK1 expression plasmid. pLVX-Tight-Puro has a transactivatior 
rtTA-Advanced response element in the PTight promoter region, and a puromycin 
resistant gene which can used for selecting stable cell line. The cDNAs of Flag-HPK1 
and Flag-M46 (HPK1 kinase dead form) were cut from previous constructed pShuttle-
CMV-Flag-HPK1/M46 (a construct for adenovirus based expression system) by restrict 
enzymes BglII and EcoRV. The digested cDNAs was inserted into pLVX-Tight-Puro 
vector right after PTight promoter region through BamHI and EcoRI sites. Ligation was 
completed in 2 steps: first, ligating BglII site with BamHI site through compatible stick 
ends; second, ligating EcorV site with EcoRI site through blunt-end ligation methods.  
The obtained pLVX-Tight-Puro-Flag-HPK1/M46 constructs were packaged to lenti virus 
using Lenti-X HTX Packaging Mix as described above. The collected lenti-viral particles 
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were used to infect pLVX-Tet-On-Panc-1 cell line. The stable colonies of pLVX-
HPK1/M46-Panc-1 cells were selected under condition medium with 2µg/mL of 
puromycin. Doxycycline induced expression of HPK1 or M46 were checked by Western 
blotting using anti-HPK1 antibody. 
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CHAPTER 3:  
To determine the oncogenic role of Axl in PDA progression 
 
Introduction 
Pancreatic cancer is the fourth leading cause of cancer death in the United States, 
preceded only by lung, colon, and breast cancers 243. Despite the available treatment 
modalities for pancreatic ductal adenocarcinoma (PDA), including chemotherapy, 
radiotherapy, surgery, or a combination of these modalities, PDA has the worst prognosis 
of all major malignancies, with 5-year survival of less than 5% 244. Even resectable PDA 
at an early stage frequently recurs either with metastatic disease in the liver, lung, or 
peritoneal cavity or with local recurrence in the pancreatic surgery bed. Therefore, 
functional studies of genetic alterations involved in its aggressive growth and metastasis 
are important to develop new treatment modalities for pancreatic cancer. 
 
Increased expression of the epidermal growth factor (EGF) family of mitogenic peptides 
and their corresponding receptor tyrosine kinases (RTKs) related to the EGF receptor is a 
common feature of PDA 245. The binding of growth factors to RTKs promotes 
dimerization and autophosphorylation in its cytoplasmic domain and the subsequent 
activation of downstream signal pathways that control a variety of cellular processes, 
such as proliferation, differentiation, migration, and survival 246, 247. Unlike other RTKs, 
which are activated by growth factors, Axl is a unique RTK in that it is activated by 
growth arrest specific factor 6 (Gas6), a member of the vitamin K–dependent proteins 85, 
88. Axl protein has an extracellular domain resembling cell adhesion molecules, which 
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consists of 2 immunoglobin-like domains and 2 fibronectin III-like motifs, and contains a 
typical intracellular kinase domain of an RTK 85, 88. Using an EGF-Axl chimeric receptor 
construct consisting of the extracellular and transmembrane domains of EGFR and the 
Axl kinase domain, Fridell et al showed that overexpression of this chimeric protein is 
sufficient to induce Axl's transforming activity and tumor formation in nude mice, 
suggesting that Gas6-independent mechanisms of Axl functions may also exist 91. 
 
Axl was originally identified as a transforming gene in chronic myelogenous leukemia 
and has been reported to be overexpressed in many types of human malignancies, 
including diffuse glioma, melanoma, osteosarcoma, and carcinomas of the lung, colon, 
prostate, breast, ovary, esophagus, stomach, and kidney 75, 80, 118, 139, 145, 248. Previous 
studies have shown that Axl signaling promotes tumor cell proliferation, migration, and 
invasion in these tumors. Both Axl and Gas6 were overexpressed in glioma cell lines and 
human glioma tissue samples and are associated with a poor prognosis in patients with 
glioblastoma multiforme 139. Inhibition of Axl signaling by a dominant-negative Axl 
mutant suppresses tumorigenesis, migration, and invasion and resulted in long-term 
survival of mice after intracerebral implantation of glioma cells compared with glioma 
cells transfected with wild-type Axl 118. Axl was also overexpressed in metastatic 
prostatic carcinoma cell line compared with normal prostatic epithelial cells and other 
prostatic carcinoma cell lines 249. In addition, Axl has been shown to be a key regulator 
involved in multiple steps of angiogenesis, including endothelial cell migration, 
proliferation, and tube formation in vitro 134. Knockdown of Axl expression not only 
impaired the formation of functional blood vessels in vivo but also reduced the growth of 
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MDA-MB-231 breast carcinoma cells in a xenograft mouse model 134. These findings 
indicate that Axl is critical for tumorigenesis, invasion, and angiogenesis. However, the 
expression and functions of Axl in PDA have not been well studied. In this study, we 
examined the expression of Gas6 and Axl proteins in 12 PDA cell lines, 54 
pancreaticoduodenectomy specimens of stage II PDA, and their paired non-neoplastic 
pancreatic ductal epithelial cells. Using univariate and multivariate analysis, we 
correlated the expression of Axl with survival and other clinicopathologic features in 
patients with stage II PDA. To further examine the function of Axl in PDA, we used 
shRNA to knock down Axl expression in PDA cell lines and measured the effect of Axl 
knockdown on radiation-induced apoptosis and invasion ability. Our data showed that 
Axl and Gas6 are frequently overexpressed both in PDA cell lines and human PDA 
samples and play an important role in anti-apoptosis and invasion in pancreatic cancer. 
Therefore, targeting Axl signaling pathway may represent a new approach for the 
treatment of PDA. 
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Results 
Axl overexpression correlated with poor prognosis in stage II PDA patients. 
To examine Axl expression in pancreatic cancer patients, a tissue microarray with 
specimens from 54 patients having stage II PDA was conducted, (See materials and 
methods section). Then the Axl expression levels were quantified and summarized 
through statistical approaches. As shown in figure 2a and b, Axl displayed a strong and 
diffuse cytoplasmic staining in pancreatic cancer duct cells, but not in normal ductal cells 
(Fig. 2 c and d). 38 of 54 stage II PDA specimens (70%) had high Axl expression. 
However; in 50 of paired non-neoplastic pancreatic ductal tissues, 11of them (22%) had 
high Axl expression. The mean Axl expression scores of PDA samples and non-
neoplastic pancreatic ductal tissues, which was 43.6 and 7.2 correspondingly (Fig. 2e), 
also showed a significant increase in the PDA samples (p=0.0001).  
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Figure 2. Immunohistochemical results showed Axl expression is increased in PDA 
samples.  
Representative micrographs show strong cytoplasmic Axl staining in a moderately 
differentiated PDA (a and b) and no expression of Axl protein in normal pancreatic duct 
(original magnification, 20× for a and c, 200× for b, and 400× for d). (e) Axl expression 
in PDA samples and their paired non-neoplastic pancreatic ductal epithelial cells are 
quantified and summarized (*P < .01). The mean scores of Axl staining in PDA and non-
neoplastic pancreatic samples are 43.6 and 7.2 respectively. 
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Clinicopathologic correlations between Axl expression and clinicopathologic pancreas in 
patients with stage II PDA progression was summarized in Table 1. Based on World 
Health Organization classification standards,  54 stage II PDA samples were classified as 
well-differentiated adenocarcinoma (8 cases, 15%), moderately differentiated 
adenocarcinoma (33 cases, 61%), and poorly differentiated adenocarcinoma (13cases, 
24%). 43 of 54 patients had R0 resection, in which surgical margins are microscopically 
negative. The remaining 11 patients had R1 resection 229. As summarized in Table 1, the 
Axl expression levels did not correlate with tumor size (p=0.71), resection margin status 
(p=1.0), lymph node status (p=0.55), postoperative chemotherapy (p=0.71), and 
postoperative radiotherapy (p=0.47). However, the frequency of distant metastasis 
between Axl high and low patients showed a significant difference (p=0.02). 22 of 38 
(58%) Axl-high PDA patients had distant metastasis, which was obviously higher than it 
in Axl-low PDA patients, in which only 4 of 16 (25%) patients had distant metastasis. 
The patients with Axl-high PDAs showed a worse prognosis. As demonstrated by 
Kaplan-Meier curves in figure 3, the median overall survival for Axl-high PDA patients 
were 25.0±4.3 months, compared to 82.9±35.3 months in Axl-low PDA patients (p=0.02; 
Fig. 3a). The median recurrence-free survival of Axl-high PDA patients was 12.6±4.3 
months, compared to 82.4±55.7 months in patients with Axl-low PDAs (p=0.008; Fig. 
3b). In multivariate analysis, high expression of Axl was associated with poor overall 
survival and recurrence-free survival (P = .03 and P = .04, respectively) independent of 
tumor size and lymph node status or stage, seeing Table (2)  
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Table 1. Clinicopathologic Correlation of Axl Expression in Stage II PDAs 
Characteristics N Axl Low (n = 16) Axl High (n = 38) P 
Age, y    0.14 
<60 20 6 14  
60-70 22 9 13  
>70 12 1 11  
Sex    0.13 
Female 18 3 15  
Male 36 13 23  
Tumor size, cm    0.71 
≤2.0 11 4 7  
>2.0 43 12 31  
Tumor differentiation 0.24 
Well 8 4 4  
Moderate 33 10 23  
Poor 13 2 11  
Margin status    1.0 
Negative 43 13 30  
Positive 11 3 8  
Lymph node status (stage) 0.55 
Negative (IIA) 20 7 13  
Positive (IIB) 34 9 25  
Postoperative chemotherapy 0.71 
No 9 2 7  
Yes 45 14 31  
Postoperative radiotherapy 0.47 
No 12 2 10  
Yes 42 14 28  
Recurrence/distant metastasis 0.02 
No 14 8 6  
Local 14 4 10  
Distant 26 4 22   
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Table 2. Univariate and Multivariate Analysis of Overall and Recurrence-Free 
Survival in Patients With Stage II Pancreatic Ductal Adenocarcinomas 
Overall Survival Recurrence-Free Survival 
Parameters N HR (95% CI) P HR (95% CI) P 
Univariate analysis 
Age, y 
<60 (reference) 20 1.00  1.00  
60-70 22 1.39 (0.66-2.91) 0.38 1.19 (0.59-2.41) 0.63 
>70 12 1.46 (0.59-3.60) 0.42 1.40 (0.58-3.38) 0.45 
      
Sex 
Female (reference) 18 1.00  1.00 0.36 
Male 36 0.84 (0.43-1.66) 0.62 0.74 (0.38-1.42)  
      
Tumor size, cm 
≤2.0 (reference) 11 1.00  1.00  
>2.0 43 3.25 (1.15-9.24) 0.03 3.82 (1.35-10.82) 0.01 
      
Tumor differentiation 
Well (reference) 8 1.00  1.00  
Moderate 33 1.80 (0.68-4.76) 0.23 1.92 (0.73-5.06) 0.19 
Poor 13 1.72 (0.57-5.16) 0.34 1.81 (0.62-5.32) 0.28 
      
Margin status 
Negative (reference) 43 1.00  1.00  
Positive 11 1.18 (0.51-2.72) 0.72 0.83 (0.36-1.88) 0.65 
      
Lymph node status (stage) 
Negative (IIA) 20 1.00  1.00  
Positive (IIB) 34 2.20 (1.04-4.62) 0.04 3.31 (1.54-7.08) 0.002 
      
Postoperative chemotherapy 
No (reference) 9 1.00  1.00  
Yes 45 1.92 (0.58-6.43) 0.29 1.50 (0.53-4.27) 0.45 
      
Axl expression 
Low (reference) 18 1.00  1.00  
High 36 2.48 (1.13-5.46) 0.02 2.79 (1.27-6.13) 0.01 
      
Multivariate analysis 
Tumor size (cm) 
≤2.0 (reference) 11 1.00  1.00  
>2.0 43 3.14 (1.10-8.93) 0.03 2.87 (0.96-8.54) 0.06 
      
Lymph node status (stage) 
Negative (IIA) 20 1.00  1.00  
Positive (IIB) 34 1.22 (0.53-2.81) 0.65 2.12 (0.95-4.71) 0.07 
      
Axl expression 
Axl low (reference) 16 1.00  1.00  
Axl high 38 2.40 (1.08-5.29) 0.03 2.36 (1.06-5.28) 0.04 
Abbreviations: HR, hazard ratio; CI, confidence interval. 
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Figure 3. Kaplan-Meier curves for overall survival and recurrence-free survival by 
Axl expression in patients with stage II PDAs indicated that Axl high patients have 
worse prognosis. 
 (a) Median overall survival time for Axl-high and low PDA patients are 25.0 ± 4.3 
months and 82.9 ± 35.3 months respectively (P = .02, log-rank method). (b) Median 
recurrence-free survival was 12.6 ± 3.5monthes for Axl-high patients, and 82.4 ± 55.7 
months for Axl-low patients (P = .008, log-rank method). 
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Axl and Gas6 were overexpressed in a transgenic mouse model of pancreatitis.  
Previous studies show that pancreatic cancer development is that pancreatic cancer 
developed from precursor pancreatic intraepithelial neoplasia (PanIN) 250 67 66. Chronic 
pancreatitis will cause genomic instability and promote pancreatic development 67, 251 66. 
K-Ras was mutated in almost all pancreatic cancer. In a cLGL-KRasG12V transgenic 
model, where KRasG12V was overexpressed specifically in pancreas through Cre/loxP 
recombination system,  extensive chronic pancreatitis (CP), PanIN, as well as PDA were 
observed 66,67. To further understand the role of Gas6/Axl signaling in the PDA 
development, The Gas6, Axl protein levels in mouse CP from cLGL-KRasG12V mice, 
which  is a courtesy of Dr. Logsdon Lab, were detected either by Western blotting, or 
immunohistochemistry. As shown in Fig. 4c, Axl protein levels in mouse pancreas with 
chronic pancreatitis was much higher than normal mouse pancreas. Axl 
immunohistochemistry results showed that duct cells in mouse chronic pancreatitis had 
more Axl staining (Fig. 4a). Gas6 immunohistochemistry results showed similar pattern 
as Axl. Gas6 staining in mouse CP tissue was stronger than it in normal mouse pancreatic 
ductal cells (Fig. 4b). In summary, Axl and Gas6 overexpression seems an early event in 
PDA development.  
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Figure 4. Axl and Gas6 protein levels were increased in Ras mouse model of 
pancreatitis and PDA. 
 (a) Immunohistochemical(IHC) staining of Axl in mouse chronic pancreatitis (CP) tissue 
showed that Axl was up-regulated. (b) IHC staining of Gas6 showed it is overexpressed 
in mouse CP tissue. (c) Axl Western blotting assay demonstrated that Axl was 
overexpressed in mouse CP tissues. 
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Most pancreatic cancer cell lines had overexpression of Axl and Gas6 
Since most human PDA samples (70%) had overexpressed Axl. We expected that Axl 
expression was also high in pancreatic cancer cell lines. To test Axl, and Gas6 expression, 
12 pancreatic cancer cell lines, as well as one immortalized normal pancreatic ductal 
epithelial cell line, HPDE, were cultured to 80% confluence, and then collected for West 
Blotting using either anti-Axl, or anti-Gas6 body, seeing materials and methods. In 
parallel, Cell samples were also collected for total mRNA extraction; and quantitative 
real time PCR was conducted to measure the mRNA levels of Axl. As shown in the 
figure 4a, comparing with HPDE cells, 9 of 12 (75%) PDA cell lines have Axl protein 
overexpression. They were Mia PaCa-2, Panc-48, Panc-1, Hs766T, ASPC-1, CFPAC-1, 
Panc-3, Panc-28, Capan-2, and BxPC3 cells. The ratio of PDA cell lines with high Axl 
expression was close to what we observed in PDA tissue samples (70%). Interestedly, 
Gas6 protein was also found for the first time to be overexpressed in most PDA cell lines 
(70%), which are MIA PaCa-2, Panc-48, Panc-1, Hs766T, Capan-1, Panc-28, Capan-2, 
BxPC3, and L3.6PL cells (Fig. 5a ). Axl mRNA levels measured by quantitative RT-PCR 
also demonstrated that most PDA cell lines had overexpressed Axl (Fig. 5b).   
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Figure 5. Overexpression of Axl and Gas6 in PDA cell lines 
(a) Axl and Gas6 protein levels in PDA cell lines and immortalized normal pancreatic 
ductal epithelial cell HPDE (control) were measured by Western blotting assay. Most 
PDA cell lines have elevated Axl and Gas6 expression. (b) Relative Axl mRNA levels in 
PDA cell lines and HPDE cells. Quantitive RT-PCRs were performed using Axl and 
RPS6 (reference gene) specific primers. HPDE mRNA levels was set as 1. Majority of 
the PDA cell lines had elevated Axl mRNA levels.  
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Axl silencing sensitized cells to apoptosis stimuli 
In breast cancer, Axl can activate Akt and NF-KB pathway to against apoptosis stimuli 
135 252 145. To test whether Axl is involved in the survival of PDA cells, we silenced Axl 
expression by shRNA. Two shAxl stable colonies each generated from Panc-28 (AS4.9, 
AS4.10), Panc-1 (Sh2.1, Sh4.3) were selected for following experiments. As 
demonstrated by Axl Western blotting in Fig. 6a and b, each shAxl stable clone had no 
detectable Axl expression; whereas, the Axl protein levels in vector alone pLKO.1-Panc-
28, and pLKO.1-Panc-1 stable clones were not changed, when compared with parental 
cell lines. To test whether Axl played a role in the cell apoptosis, above Axl silenced 
stable cell lines were treated with Gamma-irradiation with a dose of 20Gy on Panc-28 
series, or 30Gy on Panc-1 series. 48 hours After irradiation treatment, cells were 
collected for either PARP cleavage assay, or counting sub-G(1) cells as described in 
materials and methods. Though PARP cleavage, the apoptosis marker, was detectable in 
all cells after irradiation, Axl silenced stable cell lines AS4.9, AS4.10, Sh2.1, and Sh4.3 
had markedly increased PARP cleavage, compared to parental or vector controls (Fig. 6c 
and d. To quantify the amount of cells in apoptosis, the cells in Sub-G(1) were sorted and 
counted by FACS analysis. The average percentages of cells in apoptosis were 24.7% for 
AS4.9, 25.7% for AS4.10, which were significant higher than 11.8% for parental cell 
panc-28, and 13.0% for vector alone control pLKO.1-Panc-28 (Fig. 6e). Though Panc-1 
was more resistant to radiation treatment, similar results were observed. The mean 
percentage of apoptotic cell of sh2.1, sh4.3, Panc-1 and pLKO.1 cells was 16.3%, 17.1%, 
6.8% and 6.2% respectively (Fig. 6f). Axl silencing could also increase the apoptosis of 
PDA cells by serum starvation. The PARP cleavage was shown up in control pLKO.1-
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Panc28 cells under serum starvation for 48 hours. However, in Axl silenced AS4.9, 
AS4.10 cells, the PARP cleavage was advanced to time point of 24 hours (Fig 5g), 
suggesting that Axl silencing could accelerate the cell apoptosis under serum starvation 
condition. In conclusion, Axl silenced PDA cells is more sensitive to apoptosis stimuli, 
gamma-irradiation and serum starvation. Our data showed that Axl play an important role 
in the survival of PDA cells.  
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Figure 6. Axl silenced PDA cells were more sensitive to apoptosis stimuli.  
Compared to parental and vector control (pLKO.1) cells, Axl in Panc-28 (a) and Panc-1 
(b) was efficiently silenced by shRNA (clone AS4.9, AS4.10, Sh2.1 and Sh4.3), which 
was demonstrated by Western blotting assay. (c and d) After treated with indicated dose 
of γ-irradiation, cells were collected at time point of 48 hours to detect PARP cleavage (a 
marker of cell in apoptosis) by Western blotting assay. As compared to parental and 
vector control cells, Axl silenced stable clones had significantly more PARP cleavage. (e 
and f ) With the same γ-irradiation treatments, cells in sub-G(1) stage (a status reflects 
cell in apoptosis) were sorted and counted by PI-FACS analysis. Compared to controls, 
Axl silenced clones had more cells in sub-G(1) stage (*p<0.01). (g) When treated with 
serum starvation for 24 or 48 hours, Panc-28 showed a significant PARP cleavage in a 
time point of 48 hours. However, Axl silenced clones AS4.9 and AS4.10 had shifted the 
PARP cleavage to an earlier time point of 24 hours.        
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Axl silencing decreases the invasion capability of PDA cells. 
Previous works showed that dominant negative form of Axl can down regulate glioma 
cell invasion ability 118. Axl could activate NF-kB pathway, and enhance expression of 
matrix metalloproteinase 9 (MMP-9), which are related to cell invasion capability 122. 
Our tissue microarray data, which showed that Axl-high PDA patients had higher 
frequency of distant metastases than those patient with Axl-low tumors, we anticipated 
that overexpressed Axl may contribute to PDA progression by increasing the migration 
and invasion potential of pancreatic cancer cells. To test above hypothesis, a Matrigel in 
vitro invasion assay was performed.  The number of cells invaded through themembrane 
was counted and compared between Axl silenced cell lines (AS4.9, AS4.10), and control 
cell lines (Panc-28, pLKO.1-Panc-28). As shown in Fig. 7b, the average number of 
invaded cells for AS4.9, and AS4.10 were 55, and 62 respectively per microscope field, 
which were significantly lower than 286 for Panc-28, or 301 for pLKO.1-Panc-28 
(P<0.01).  
 
Matrix metalloproteinase-2 (MMP-2) facilitates the cell invasion by digesting off the 
matrix collagen around cells 253. Increased MMP-2 expression was often observed in 
cancer 254 253. To test whether Axl regulate the MMP-2 levels, the secreted proteins were 
collected and concentrated as described in materials and methods. Western blotting was 
performed using antibody specific to MMP2, and IGFBP6 234, 235which served as protein 
loading control. As shown in Fig. 7c, the proteins levels of MMP2, but not loading 
control IGFBP6 was lower in Axl silenced AS4.9 and AS4.10 cells, when compared to 
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control pLKO.1-Panc-28 cells. Above results indicated that Axl may enhance cancer cell 
invasion capability by increasing secreted MMP-2 levels.    
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Figure 7. Axl silencing reduced the invasion potential of PDA cells.  
(a)Representative micrographs were selected from 4 cell lines used in in vitro Matrigel 
invasion assay.  The number of cells invaded to trans-well membrane was lower in Axl 
silenced stable clones AS4.9 and AS4.10 than the controls Panc-28 and pLKO.1 clone. (b) 
The cells invading into trans-well membrane were counted under a microscope in 5 
predetermined fields at ×200 magnification. Each sample was assayed in triplicate, and 
assays were repeated at least twice. The average number of cells invaded through the 
membrane was plotted. A significant decrease of invaded cells in AS4.9 and AS4.10 
clones was observed (*P <0.01). (c)Axl silencing specifically down regulate MMP-2 
expression. MMP-2 secreted into medium was concentrated by Millipore centrifugal 
filter device and detected by Western blotting assay. Comparing to panc-28, Axl silenced 
AS4.9 and AS4.10 has less MMP-2. Western blotting assay on IGFBP6 demonstrated 
that equal amount of total secreted protein was used in assay. Here, the Axl expression in 
cells used for collecting MMP-2 was also detected by Western blotting. Equal actin levels 
indicated that all cell pellets has equal amount of total protein.  
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Axl silencing decreased the migration ability of PDA cells 
Since Axl overexpression correlates with distant metastasis in patients with PDA and Axl 
increases invasion capability, we examined the probability that Axl can increase cancer 
cell migration ability. To test the effects of Axl on cancer cell migration, an in vitro 
migration assay were conducted. The cells migrated through membrane were 
photographed, and the number of migrated cells were counted. As shown in the 
representative microscope field of each cell line tested (Fig.7a), Axl silenced AS4.9, 
AS4.10 cell lines had much fewer cells migrated through membrane, when compared 
with control cell lines pLKO.1-Panc-28, and Panc-28. Migration assay was repeated three 
times. The average number of cells on each preselected microscope was summarized in 
Fig. 8b. They were 221 for Panc-28, 203 for pLKO.1-Panc-28, 42 for AS4.9, and 51 for 
AS4.10. The number of migrated cells in Axl silenced cell lines was lower than the 
control cells (p<0.01). 
 
When cells in migrating, filopdial extensions were formed in front ends. So the 
morphology of migrating cells displayed a polar spindled shape 255-257. We expected that 
Axl silencing may change cell morphology. As shown in Fig.7c, control cells pLKO.1-
Panc-28 had polarized spindle shape. However; Axl silenced AS4.9, AS4.10 displayed a 
typical depolarized round shape. The morphological change in Axl silenced cells may 
imply less formation of filopdial extensions. In conclusion, Axl silencing can make 
pancreatic cancer cells lose migration ability. 
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Figure 8. Axl silencing in PDA cells caused less migration potential. 
(a) Representative micrographs of in vitro migration assay showed that Axl silenced cells 
AS4.9 and AS4.10 had less migrated cells than controls Panc-28 and vector alone, 
pLKO.1 cells. Here 2% FBS was served as chemo-attractant for cell migration. (b) 
Migrated cells in 5 predetermined fields of each assay were counted under microscope. 
The average number of cells in each filed were calculated. As summarized in this figure, 
Axl silenced cells AS4.9 and AS4.10 had significantly lower number of migrated cells 
(p<0.01). (c) Panc-28 cells displayed a spindle shape; whereas, AS4.9 and AS4.10 cells 
displayed a spherical shape, indicating Axl silenced cells has less filopdial extensions.
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Axl silencing abolished basal and Gas6 activated Akt activation in PDA Cells.  
Akt signaling pathway played important roles in cell survival and cell transformation. 
Activated receptor tyrosine kinase, like EGFR can recruit and activate phosphoinositide 
3-kinase (PI3-K), which further phosphorylate and activate a serine/threonine protein 
kinase Akt 31, 258-262. As a receptor tyrosine kinase, Axl may also activate Akt. To test 
whether Axl silencing can abolish Gas6 stimulated Akt activation. Axl silenced AS4.9, 
AS4.10 as well as controls pLKO.1-Panc-28 were grown to 80% confluence, and then 
changed to serum free medium for overnight. Finally, cells were treated with 400 ng/mL 
of human recombinant Gas6 (R&D systems Co. Cat#885-GS) for 5, 10, or 30 minutes. In 
parallel, another set of samples treated with 50ng/mL EGF served as positive control. As 
shown in Fig.9a, after Gas6 stimuli, the levels of phospho-Akt increased dramatically in 
control pLKO.1-Panc-28 cells, but not in Axl silenced AS4.9, and AS4.10 cells. However, 
as positive control, EGF could stimulate Akt phosphorylation in all cells. Comparing the 
phospho-Akt levels in samples (lanes labeled as 0 min) without Gas6, or EGF stimuli, the 
basal levels of phopspho-Akt in Axl silenced AS4.9, AS4.10 cells were lower than 
control pLKO.1-Panc-28 cells. Similar results were observed in another PDA cell line in 
experiment (Fig. 9b). Under same condition of Gas6 stimuli, Panc-1 cells had more basal 
and stimulated phospho-Akt than Axl silenced sh2.1 cells. The Akt activation mediated 
by Gas6/Axl signaling further supported that Axl can promote cell survival and invasion 
which in part may be due to activation of Akt. 
79 
 
Figure 9. Axl silencing abolished Gas6 mediated Akt activation. 
(a) After serum starvation for overnight, vector alone cell Panc-28-pLKO.1, and Axl 
silenced Panc-28 cells AS4.9, AS4.10 were treated with either EGF (50ng/mL) or Gas6 
(400 ng/mL) for the indicated time. After stimulation, phospho-Akt and total Akt in cells 
were detected by Western blotting assay. EGF activated Akt in both Axl silenced Panc-28 
cells and Panc-28-pLKO.1 cell; However, Gas6 stimulated Akt only control Panc-28-
pLKO.1 cell, but not in Axl silenced Panc-28 AS4.9 and AS4.10 cells. The basal levels of 
phospho-Akt in AS4.9 and AS4.10 cells were also lower than Panc-28-pLKO.1 cell 
(lanes with 0 min of treatment). The total Akt levels are similar in all cells, either treated 
with EGF, or Gas6. (b) Similar phospho-Akt pattern was observed in panc-1 cells, where 
Axl silencing (cell Sh2.1) also abolished Gas6 stimulated Akt activation. 
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Axl silencing diminished basal NF-κB activity 
Transcription factor, nuclear factor of κB light chain (NF-κB), played important roles in 
cell transformation, survival, migration, invasion and tumor metastasis 263 264 265. NF-κB 
is constitutively activated in many cancers, including pancreatic cancer 266. NF-κB could 
be activated by Akt signaling 265. Axl silencing down regulated Akt signaling, so NF-κB 
activity was expected to be down regulated as well. To test whether Axl affect NF-κB 
activity, a luciferase assay was performed. The intensity of luminescence recorded by 
IVIS bioluminescence system showed that luciferase activity was hardly detectable in 
Axl silenced Sh2.1, and Sh4.3 cells. However, the corresponding control cells, Panc-1 
and Panc-1-pLKO.1, had relative strong luciferase activity (Fig. 10). Above results 
demonstrated that Axl could regulate the NF-κB activity. Axl silencing reduced the 
constitutive NF-κB activity in PDA cells.  
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Figure 10. Axl silencing in PDA cells reduced basal NF-κB activity. 
NF-kB-Luc-reporter plasmids were transfected to Panc-1, Panc-1-pLKO.1(vector alone 
control), and Axl silenced Sh2.1,  Sh2.3 cells. After adding substrate D-luciferin, 
bioluminescence coming from luciferase activity was recorded by IVIS bioluminescence 
system in same set-up. The representative photographs here showed that Panc-1, Panc-1-
pLKO.1, Sh2.1, and Sh4.3 had correspondingly 3.74e+05, 3.57e+05, 3.78e+04, and 
8.49e+04 photons. 
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Discussion 
Pancreatic cancer was one of most malignant cancer 3. The five-year survival rate for 
pancreatic cancer patients was less than 5% 3. However, the molecular mechanisms of 
pancreatic cancer development and progression were not well known. The therapeutic 
options for pancreatic cancer are quite limited, and not effective 267. Exploring new 
therapeutic approach or finding new therapeutic targets is urgently demanded. 
Deregulated receptor tyrosine kinases received many interests for their prominent 
oncogenic functions and their applications in cancer therapy 73. Treatment with EGFR 
inhibitor erlotinib slightly improved clinical outcomes of pancreatic cancer patients 268, 269. 
Receptor tyrosine kinase Axl was found to has oncogenic functions on many cancers, 
including lung, breast, brain, colon, skin, prostate, ovary, and other cancers with soild 
tumors118, 127, 139, 248, 252, 270-274. However, the role of Axl in pancreatic cancer is unknown.   
 
Our tissue microarray data demonstrated that Axl was overexpressed in about 70% of 
patients with PDAs. Statistical analysis of Axl expression with clinicopathologic 
correlation revealed that Axl-high stage II PDA patients had significant shorter overall 
and recurrence-free survival (P=0.03 and 0.04 respectively). Axl-high stage II PDA 
patients also displayed a significant higher rate to have long distance metastasis (p=0.02). 
Our findings about the role of Axl in pancreatic cancer was corroborated by Koorstra 
group’s research, which demonstrated that Axl overexpression was detected in 55% of 
pancreatic cancer patients 126. The differential overexpression rate of Axl revealed by two 
groups could be explained by criteria variation. Koorstra’s research also demonstrated 
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that Axl-high patients had significant less survival rate and more lymph node metastasis 
126, which was consistent with our findings.    
 
We also checked the Axl and Gas6 protein expression in PDA cell lines and immortalized 
normal pancreatic ductal epithelial cell line (HPDE) by Western blotting assay. Both Axl 
and Gas6 overexpression were detected in 75% of cancer cell lines. Quantitative real 
time-PCR results also demonstrated that Axl mRNA levels were elevated in most 
pancreatic cancer cell lines. However, the elevated Axl mRNA levels in some PDA cell 
lines, like Panc-48 and Capan-2, are not consistent with the Axl protein levels. Both 
Panc-48 and Capan-2 have highly elevated Axl protein levels, but only slightly increased 
Axl mRNA levels. Such inconsistence suggests that Axl overexpression in PDA cell lines 
could be regulated in both mRNA and protein levels. Another inconsistence is that not all 
PDA cell lines with Axl overexpression have Gas6 overexpression, like CFPAC-1, Panc-
3 and Mpanc-96 cell lines. In those Gas6 absent PDA cell lines, we still believe 
significant levels of Axl tyrosine kinase activity are maintained, because overexpressed 
Axl can dimerize without the assistance of Gas6 80.       
To investigate the functions of Gas6/Axl signaling in pancreatic cancer, we silenced the 
Axl expression using a lenti-virus based shRNA expression system. After treating cells 
with γ-irradation, we found that Axl silenced Panc-28 and Panc-1 cells had more Poly 
ADP ribose polymerase (PARP) cleavage (an apoptosis marker) 275, 276, and more cells in 
Sub-G0/G1 phase (cells in apoptosis) 277 278. Serum starvation also caused more PARP 
cleavage in Axl silenced Panc-28 cells. All together, we concluded that Axl silenced cells 
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are more sensitive to apoptosis stimuli, like γ-irradation and serum starvation. In other 
word, Axl overexpression may contribute to pancreatic cancer cell survival.  
 
Since Axl-high pancreatic cancer patients had higher frequency of distant metastasis, we 
expected that Axl may contribute to pancreatic cancer cell invasion and migration. We 
performed matrigel invasion and migration assay to test the invasion and migration 
potential of Axl silenced Panc-28 cells. As we expected, Axl silenced cells were revealed 
to have significant less cell invasion and migration capability. Furthermore, we 
demonstrated that Axl silenced Panc-28 cells turns to round shape morphology, 
indicating there are less filopdial extensions which is required for cell in migration255-257. 
Consistent with the lower invasion rate in Axl silenced cells, Axl silencing reduced the 
amount of secreted Matrix metalloproteinase-2 (MMP-2), which is involved in the cell 
invasion by digesting the matrix collagen surrounding cells 253 254 279 280.  
 
Akt signaling was often activated by receptor tyrosine kinases like EGFR, insulin growth 
factor receptor (IGFR), Platelet-derived growth factor receptors (PDGFR), c-Met and 
other oncogenic receptors 281 282 283 284, 285. Activated Akt, phospho-Akt, contributes 
cancer cell survival, proliferation, and invasion 286 259 31 287 288. We checked phospho-Akt 
levels in Axl silenced Panc-28 and Panc-1 cells after Gas6 stimulation. As we anticipated, 
Axl silencing abolished Akt activation in both cell lines after Gas6 stimulation. 
Interestingly, the basal levels of phsopho-Akt in Axl silenced cells were also perceivably 
lower. One probable explanation is that constitutively expressed endogenous Gas6 
activates the Axl signaling. We also checked the NF-κB activity in Axl silenced Panc-28 
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cells by luciferase reporter assay. NF-κB can be activated by Akt. After Akt 
phosphorylating IκB kinase (IKK), NF-κB will be released from inhibitory IκB proteins 
and translocated to nucleus. As a transcription activator, NF-κB will transcribe many 
genes that contribute to cell transformation, survival, migration, invasion and tumor 
metastasis 263, 264, 265, 289.  NF-κB is frequently activated in many solid tumors, including 
pancreatic cancer 266, 290. As we expected, Axl silenced Panc-28 cells has significant less 
luciferase activity, suggesting Axl silencing reduced the NF-κB activity. However, we 
cannot conclude that down-regulated Akt activity is the only reason for reduced NF-κB 
activity, because Axl can also activate mitogen-activated protein (MAP) kinase pathway 
which is able to activate NF-κB as well 30, 92, 291, 292.  To consolidate the conclusion that 
Axl silenced Panc-1 cells has less NF-κB activity; we still need co-transfect a renilla 
luciferase report as an internal control. Moreover, an electrophoretic mobility shift assay 
(EMSA) for measuring the NF-κBbinding activity is necessary. Since MMP-2 
transcription can be activated by NF-κB 293, the reduced NF-κB activity in Axl silenced 
PDA cells could account for the MMP-2 down regulation. 
    
Our research further confirmed that Axl overexpression was a common phenomenon 
among different type of cancers. Before our research in pancreatic cancer, Axl 
overexpression was observed in lung, breast, brain, colon, skin, prostate, ovary, and other 
cancers with soild tumors 118, 127, 139, 248, 252, 270-274. About the question how Axl 
overexpression changed the pancreatic cancer cellular behaviors, we found that Axl 
silencing can cause cells more sensitive to apoptosis stimuli and less cell invasion and 
migration capability. More than that, Koorstra’s research found that Axl can contribute to 
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pancreatic cell transformation and anchorage independent growth. Though dominant 
negative form of Axl will inhibit brain tumor growth in a xenograft mouse model, Axl 
silencing did not significantly affect pancreatic cancer cell growth rate (data not shown) 
118. One probable reason is that the Panc-28 and Panc-1 cells in tests have a bundle of 
proliferation signaling. Redundancy of proliferation signaling compromises the Axl 
silencing. The weak effects on cancer cell proliferation may be not rare for Gas6/Axl 
signaling. Overexpressing Gas6 in NIH3T3 did not cause increased DNA synthesis 294.       
 
So far there are still many remaining questions about how Axl contribute to pancreatic 
cancer progression, especially the molecular mechanisms. Akt and NF-κB activation by 
Gas6/Axl signaling definitely provided some potential mechanisms for Axl contributing 
to pancreatic cancer cell survival 95, 295, 296. However, we cannot ignore that Axl can also 
activate MAP kinase pathway, which is involved in cell survival 92. About how Axl 
contribute to pancreatic cancer metastasis, one probable explanation is that Axl can 
regulate Epithelial-Mesenchymal Transition (EMT) by up-regulating transcription of 
transcriptional factors Twist, Slug, and Snail, which are required for EMT 126, 297. During 
EMT process, cancer cells will lose cell-cell adhesion and cell polarity, and convert cells 
to an invasion/migration status 298, 299, 300. To systematically elucidate the molecular 
mechanism for how Axl contributes to pancreatic cancer progression, microarray data for 
discovering genes altered by Axl will be necessary.  
 
The most interest issue raised by our research is that Axl can be used as therapeutic target. 
Down-regulating Gas6/Axl signaling in pancreatic cancer will be a direction that worth 
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putting extensive efforts on. We are not alone in developing drugs against Axl signaling. 
An anti-Axl monoclonal antibody developed by Li et al was tested to be able to inhibit 
breast cancer and non-small cell lung cancer (NSCLC) growth in xenograft mouse model 
145, 146. Tyrosine kinase small molecular inhibitor, R248, developed by Holland SJ et al 
also displayed an obvious inhibitory effect on breast tumor growth, cell invasion and 
tumor metastasis 135. Some small molecules originally screened for inhibiting other 
oncogenic tyrosine kinases, like c-Ret, c-Kit, Met, Rad51, PDGFR, Src, and Abl, were 
also identified as Axl inhibitors, such as Amuvatinib, Bosutinib, Foretinib and BMS-
777607 144, 270, 301-304. To best characterize effects brought by Axl inhibitors, we will test 
them in a pancreatic cancer xenograft mouse model. We expect Axl specific inhibitors 
will prevent PDA growth in xenograft mouse model. 
 
Pancreatic cancer is extremely resistant to chemotherapy, which can be reflected by the 
extremely low survival rate. Only 5% of diagnosed pancreatic cancer patients can survive 
more than 5 years 3. Epithelial-Mesenchymal Transition (EMT) is recognized as one 
reason of chemotherapy resistance 305, 306 307 308. Reversing EMT will be a strategy to 
overcome chemotherapy resistance. For example, reversing EMT of non-small cell lung 
cancer (NSCLC) cells by overexpressing cadherin-1 obviously reduced the resistance to 
erlotinib, an EGFR kinase inhibitor 309. Silencing of EMT trigger gene ZEB-1 in 
pancreatic cancer cells increased the cell sensitivity to a common chemotherapy drug, 
gemcitabine 307. Interestingly, Axl silencing in pancreatic cancer cells significantly 
downregulated mRNA levels of Twist, Slug, and Snail, who can also trigger EMT 
process. All above analysis rationalized that inhibiting Gas6/Axl signaling would be a 
90 
 
good way to against chemotherapy resistance in pancreatic cancer. So Axl inhibitors 
could be used as an adjuvant therapy of traditional chemical or irradiation therapy for 
PDA patients. 
 
In a word, our research for the first time demonstrated that Axl overexpression correlated 
with poor survival time and distant metastasis in PDA patients. Axl promotes cell 
survival under irradiation, and cell migration/invasion. Our research firstly demonstrated 
that Axl could be adopted for prognostic marker for PDA patients. Moreover, Axl can be 
used as potential therapeutic target for PDA. Developing Axl specific inhibitors will be a 
topic that worth large investment.    
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CHAPTER 4:  
To investigate the role of HPK1 in Axl degradation through endocytosis pathway 
 
Introduction 
In previous charter, we showed that Axl protein levels are dramatically increased in PDA 
tissues and PDA cell lines. Axl overexpression contributes to PDA progression. Down-
regulating Axl expression is one potential approach for PDA treatment 115, 145. Therefore, 
understanding the mechanism of regulating Axl expression is critical for developing 
probable therapeutic method against Axl. Receptor tyrosine kinase undergoes endosomal 
sorting and lysosomal degradation 188, 193. However, the deregulated endocytosis pathway, 
or mutations leading to insufficient connection with endocytosis pathway can stabilize 
the receptor tyrosine kinase and prolong the down-stream signaling. For example, 
VPS37A, a component of endosomal sorting complex required for transport 1 (ESCRT-1) 
is frequently deleted or down regulated in heptohepatocellular carcinoma (HCC) and 
ovarian cancer. VPS37A down regulation causes EGFR cytoplasmic retention and 
exacerbate cancer progress 224, 310. So far, the molecular regulations of Axl expression in 
both mRNA and protein levels are unclear. Little is known about Axl endorsomal sorting 
in both normal cells and transformed cells. Since Axl plays an important role in PDA 
progression, it would be critical to understand the molecular mechanisms involved in the 
regulation of Axl expression in PDA. 
 
Recently our lab’s research found that HPK1 functions as tumor suppressor in PDA. 
HPK1 is expressed in normal pancreatic duct but is lost over 95% of PDAs. Restore 
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HPK1 expression in PDA cancer cell lines inhibits cell proliferation. HPK1 constitutively 
binds to HPK1-interacting protein of 55 kDa (HIP-55) and Grb2 proteins, both of which 
are involved in endocytosis 193, 311-313,  suggesting HPK1 may be also involved in 
endocytosis pathway. Consistent with this notion that HPK1 silenced B lymphoma cells 
has slower IgM internalization rate 227. In immune system, HPK1 functions as negative 
regulator of T- cell receptor (TCR) and B-Cell receptor (BCR) induced signaling, HPK1-
HIP-55 complex co-localize with TCR. HIP-55 was detected to localize in early 
endosome 226. HIP-55 promoted TCR down-modulation through endocytosis in both 
basal and ligand-dependent ways 226. All those data suggested that HPK1 may participate 
in receptor mediated endocytosis. Here I expected that HPK1 plays an important role in 
regulating Axl protein levels through endocytosis pathway. Moreover, the molecular 
mechanism of how HPK1 function as tumor suppressor is unknown. Down-modulating 
Axl signaling could be an approach adopted by HPK1. 
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Results 
Axl physically associated with HPK1.  
In order to identify the binding partners of HPK1 in PDA cells, an antibody array was 
performed. Flag-HPK1 in Flag-HPK1-Panc-1 #18 cell line was stabilized by MG132.  
Cell lysates were collected to incubate with an antibody membrane. Complexes 
containing antibody, antibody targeted proteins, and its associated HPK1 protein were 
formed on membrane. Anti-flag antibody was used to probe associated HPK1. As shown 
in Fig. 11a, HPK1 interacted with Axl in Panc-1 cells. In addition, our antibody array 
data also showed that HPK1 interacted with dynamin 2. To further confirm that Axl 
physically interacted with HPK1, a reciprocal co-immunoprecipitation assay was 
performed. 3µg of pCMV-Axl, 1µg of pCI-Flag-HPK1, or in combination were co-
transfected by calcium phosphate transfection into 293T cells which were grown in Ф 
6cm culture dish. The pcDNA3.1(+) empty vector were served as complement DNA, and 
made total amount of DNA in each transfection equal to 4µg. 36 hours after transfection, 
cell pellets were collected; and whole cell lysates were prepared. The co-
immunoprecipitation with either anti-Axl, or anti-HPK1 were performed. Experimental 
results demonstrated that anti-Axl can pull down HPK1 protein. In reciprocal assay, anti-
HPK1 can pull down Axl protein (Fig. 11b). Above experimental results demonstrated 
that Axl physically associated with HPK1. To test whether HPK1 interact with 
endogenous Axl protein, Jurkat cells were collected for co-immunoprecipitation with 
either anti-Axl or anti-HPK1 antibody. Jurkat cells express both Axl and HPK1. As 
shown in Fig. 11c, endogenous HPK1 interacted with endogenous Axl in Jurkat cells.  
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Figure 11. HPK1 physically interacted with Axl. 
(a) Antibody array results showed that Axl and dynamin 2 were two binding partners of 
HPK1.  Flag-HPK1-Panc-1 stable cell line was treated with MG132 to stabilize Flag-
HPK1 protein. Then the cell lysates were collected and incubated with antibody array 
membrane (Hypromatrix Co.). HPK1 interacting proteins was probed and detected by 
anti-Flag-HRP.  The dots for Axl and dynamin 2 were indicated by arrow. (b) Interaction 
between HPK1 and Axl was detected by reciprocal co-immunoprecipitation. In 293T 
cells, Axl, HPK1, or in combination, were transiently overexpressed. Cell lysates were 
collected for co-immunoprecipitation with either anti-Axl (upper panel) or anti-HPK1 
(below panel) antibody. The immunoprecipitated proteins were detected by Western 
blotting using either anti-HPK1, or anti-Axl antibody. (c) Endogenous interaction 
between HPK1 and Axl was detected in Jurkat cells. 500µg of cell lysates were incubated 
with either anti-Axl or anti-HPK1 antibody. The co-immunoprecipitated proteins were 
detected by Western blotting using anti-HPK1 and anti-Axl antibodies. The amount of 
input was 10% of lysates used in co-immunoprecipitation assay.   
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Axl mainly interacted with the C-terminal domain of HPK1 
HPK1 is composed of kinase domain (KD, 1 to 274 amino acids) and C-terminal domain 
(CD, 275 to 833 amino acids) 314. C-terminal domain includes 4 Proline rich region and 
citron homology domain. The domain structure of HPK1 is shown in Fig. 12a. To 
identify which domain of HPK1 interact with Axl, 1µg each of pCI-Flag-HPK1, pcDNA-
Flag-HPK1-KD, pcDNA-Flag-HPK1-CD was transfected alone, or in combination with 
3µg of pCMV-Axl to 293T cells grown on Ф 6cm culture dish. Empty vector 
pcDNA3.1(+) was used as complement DNA just like above. 36 hours after transfection, 
cell pellets were collected for followed co-immunoprecipitation. Flag-HPK1, Flag-
HPK1-KD, and Flag-HPK1-CD were immunoprecipitated by M2 beads. The co-
immunoprecipitated Axl protein was detected by Western blotting using antibody specific 
to Axl. As shown in Fig. 12b, Axl protein was co-immunoprecipitated with Flag-HPK1-
CD; a detectable amount of Axl protein was co-immunoprecipitated with Flag-HPK1; 
however, the Axl co-immunoprecipitated with Flag-HPK1-KD was not detectable. Above 
experiment indicated that Axl interacted with HPK1 mainly through C-terminal domain 
of HPK1. 
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Figure 12. HPK1 C-terminal domain interacted with Axl.   
(a)Schematic presentation of HPK1 structure. C-terminal domain includes four Proline 
rich regions and one Citron homology domain. (b)HPK1 interacted with Axl mainly 
through the C-terminal domain. In 293T cells, Axl expression plasmid was transfected 
alone, or co-transfected with Flag-HPK1, kinase domain (Flag-HPK1-KD), or C-terminal 
domain (Flag-HPK1-CD) expression plasmids. Cell lysates were collected for co-
immunoprecipitation with M2-beads (have specific affinity for Flag peptide). 
Immunoprecipitated Axl was detected by Western blotting assay. HPK1-CD but not 
HPK1-KD pulled down a significant amount of Axl 
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Axl can be phosphorylated by HPK1 in vitro.  
Since HPK1 is a serine/ threonine kinase 314, and HPK1 physically associate with Axl. It 
would be interesting to examine wether HPK1 can phosphorylate Axl. A HPK1 in vitro 
kinase assay was performed as described by materials and methods. HPK1, M46 (kinase 
dead form of HPK1), HPK1-KD, HPK1-CD, as well as Axl were prepared by 
transfecting expression plasmids, pCI-Flag-HPK1, pcDNA-Flag-HPK1-KD, pcDNA-
Flag-HPK1-CD, and pcDNA-Flag-Axl, individually into 293T cells. Protein expression 
levels were checked by Western blotting to ensure similar amount of HPK1, M46, HPK1-
KD, and HPK1-CD were obtained for in vitro kinase assay. All above flag tagged 
exogenous protein were immunoprecipitated by M2 bead pull-down. The in vitro kinase 
assay showed that HPK1 and HPK1-KD, but not kinase dead forms, M46 and HPK1-CD, 
can phosphorylate Axl (Fig. 13). So we could conclude that Axl may be a substrate of 
HPK1.  
100 
 
Figure 13. Axl was in vitro phosphorylated by HPK1. 
Flag tagged Axl, HPK1, M46 (kinase dead form of HPK1), HPK1-KD, HPK1-CD were 
individually expressed in 293T cells by transient transfecting corresponding expression 
plasmid. Each protein was precipitated by M2 beads. In vitro kinase was conducted by 
mixing Axl with one of HPK1 protein. The incorporated radioisotope labeled ATP was 
visualized after exposing SDS-PAGE gel to X-ray file. HPK1 and HPK1-KD but not 
M46 and HPK1-CD can phosphorylate Axl.     
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Axl expression is down regulated by HPK1 which requires HPK1 kinase activity. 
Since HPK1 interacts with and phosphorylates Axl, we hypothesized that Axl expression 
can be down regulated by HPK1. To test this hypothesis systematically, fixed amount of 
pCMV-Axl (0.3µg) was co-transfected with different amount pCI-Flag-HPK1, from 0, 
0.1, 0.3, 1 to 2µg, into 293T cells, using plasmid pcDNA3.1(+) served as complement 
DNA. 36 hours after transfection, the 293T cells were collected. Axl and HPK1 protein 
levels in each sample were checked by Western blotting using anti-Axl anti-HPK1 
respectively. As displayed in Fig. 14a, the protein levels of HPK1 sequentially increased 
as more pCI-Flag-HPK1 was transfected; correspondingly Axl protein levels gradually 
decreased and became hardly detectable when 2µg of pCI-Flag-HPK1 was co-transfected. 
Dose dependent decrease in Axl protein levels suggested that Axl expression was down 
regulated by HPK1. Similarly, treatment of Flag-HPK1-Panc-1 cells with MG132 which 
stabilized HPK1 protein leaded to marked decrease of Axl (Fig. 14b). In addition, we 
showed that endocytosis/lysosome inhibitor NH4Cl can inhibit HPK1 mediated Axl 
degradation (Fig. 14b).   
 
To test whether Axl down regulation relied on HPK1 kinase activity, HPK1 kinase dead 
form M46 was co-transfected with Axl using the same condition as HPK1 above. As 
shown in Fig. 14c, increasing amount of M46 did not change the Axl protein levels, 
suggesting kinase activity was required for Axl down regulation. In summary, Axl 
expression was down regulated by HPK1, and the HPK1 kinase activity was required for 
Axl down regulation. 
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Figure 14. Axl was down regulated by HPK1 and its kinase activity was required. 
 (a) Overexpressed HPK1 down regulated Axl expression. In 293T cells, different amount 
of pCI-HPK1 (from 0, 0.1, 0.3, 1 to 2 µg) expression plasmid was co-transfected with 0.3 
µg of pCMV-Axl expression plasmid. The protein levels of Axl and HPK1 were detected 
by Western blotting using anti-Axl and anti-HPK1 antibodies. HPK1 down-regulating 
Axl showed a dose dependent manner. (b) Axl was down regulated in Panc-1 cells. Once 
HPK1 protein in Flag-HPK1-Panc-1 stable clone was stabilized by M132 (1µM for 24 
hours), Axl was not detectable any more. However, when endocytosis/lysosome inhibitor 
NH4Cl was present, significant amount of Axl expression was restored. (c) 
Overexpression of M46, a kinase dead form of HPK1, did not down regulate Axl 
expression. The same experiment procedure was used as (a), except transfecting pCI-
M46 here instead of pCI-HPK1. 
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Axl protein half-life is shortened by HPK1 
There are several ways to determine the protein expression levels, including mRNA 
levels, translational activity, and protein stability. Since HPK1 associated physically with 
and phosphorylated Axl, HPK1 down regulating Axl expression was most likely a 
posttranslational behavior. To test the stability of Axl protein when HPK1 was present or 
not, 1µg of pCMV-Axl was co-transfected with either 3µg of pcDNA-Flag-HPK1, or 3µg 
of pcDNA3.1 (complement DNA) into 293T cells in Ф 6cm culture plate. 16 hours after 
transfection, the cells were equally split onto 6 wells. Three hours later, CHX was added 
for different time period as indicated on Fig. 15a. Axl protein levels detected by Western 
blotting demonstrated that, when HPK1 was present, Axl protein degraded much faster 
(Fig. 15a). After repeating multiple times of Axl half-life assay, the relative Axl protein 
levels were quantified and plotted. The estimated half-life of Axl, when HPK1 was 
present, was about 2.4 hours which was about 2.3 hours shorter than it without the 
presence of HPK1 (Fig. 15b).  
 
The mRNA levels of Axl were also measured by quantitative RT-PCR. The results 
showed that the presence of HPK1 did not change the Axl mRNA levels (Fig. 15c). So it 
could be concluded that Axl protein degradation rate was accelerated by HPK1, or in 
another word, Axl lost stability when HPK1 was present. 
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Figure 15. Axl protein half-life was shortened by HPK1. 
 (a) pCMV-Axl alone, or together with pCI-HPK1 was transfected into 293T cells. Then 
the cells were treated with 100µg/ mL of Cycloheximide (CHX) to inhibit protein 
translation. After inhibition for different time points, from 0, 0.5, 1, 2, 4 and 6 hours , cell 
lysates were collected for Western blotting to measure Axl protein levels. When HPK1 
was present, the Axl protein levels decreased more dramatically. (b) The relative protein 
levels of Axl in each sample were quantified with Image J software. The average value 
from multiple experiments were plotted. The half-life of Axl protein was about 4.7 hours; 
however, when HPK1 was present, the Axl protein half-life was decreased to about 2.4 
hours. (c) The relative Axl mRNA levels were not changed by HPK1. 0.3 µg of pCMV-
Axl expression plasmid was transfected alone into 293T cells or in combination with 2µg 
of pCI-HPK1. 36 hours after transfection, cells were collected for quantitative RT-PCR 
on Axl and RPS6. RPS6 was served as reference gene. NH4Cl (10mM) was added 16 
hours before harvesting cells. 
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Axl degradation caused by HPK1 is blocked by lysosome and endocytosis inhibitors. 
One common pathway for receptor degradation was endocytosis coupled lysosomal 
degradation 315, 316. To test whether Axl degradation by HPK1 was going through 
lysosome, lysosome function was disrupted by leupeptin, which can inhibit serine, 
cysteine and threonine proteases located in lysosome 317, 318. In 293T cells which were 
grown in 6 well plates, 0.3µg of pCMV-Axl was transfected alone or in combination with 
1µg of pCI-Flag-HPK1. 8 hours after transfection, cells were treated with leupeptin to a 
final concentration of 100ug/mL for 16 hours. Axl, HPK1 and actin (loading control) 
protein levels were detected by Western blotting.  Experiment was repeated for more than 
3 times. The intensity of Axl and actin Western blotting signal was measured by ImageJ 
software (NIH). The relative levels of Axl was calculated as a ratio between Axl and 
actin expression levels, and the mean value was plotted on a bar figure. As shown in Fig. 
16a, transient overexpression of HPK1 can down regulate Axl expression dramatically, 
which was consistent with the previous findings in Fig. 14a. However, when leupeptin 
was present, HPK1 mediated Axl degradation was inhibited and Axl protein levels were 
comparable to control which was transfected with pCMV-Axl alone and no leupeptin was 
added. When HPK1 was not overexpressed, leupeptin alone could slightly increase Axl 
protein levels (125% in Fig. 16b). 
  
Since lysosomal degradation is a consequence of cargo entering endosomal sorting 319, 320, 
we expected that Axl lysosomal degradation was blocked when endocytosis pathway was 
interrupted. Baflomycin A1 can specifically inhibit vacuolar-type H+-ATPase which 
keeps a low pH environment in endosomal vesicles321-323. In order to test whether HPK1 
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caused Axl degradation went through endocytosis pathway, an identical experiment was 
performed using Baflomycin A1. The dose of Baflomycin A1 used here was 0.1µM at 
final concentration. As shown in Fig. 16c and d, significantly amount of Axl come back 
when cells were treated with Baflomycin A1, even high levels of HPK1 was present. We 
also tested another frequently used endocytosis inhibitor Monensin. Monensin is a 
Na+/H+-exchanging ionophore, and can make endosome lose H+ gradients 324. The effect 
of Monensin on Axl down regulation are shown in Fig. 16e and f. Here the final 
concentration of Monensin was 100µM. When Monensin was added, HPK1 could not 
efficiently down regulate Axl expression. In addition, Monensin also inhibited Axl 
glycosylation. In conclusion, HPK1 caused Axl protein degradation was blocked by 
either lysosome or endocytosis inhibitors, implying Axl degradation was going through 
endocytosis coupled lysosome.  
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Figure 16. Lysosome and endocytosis inhibitors blocked HPK1 caused Axl down 
regulation.  
(a) Lysosome inhibitor Leupeptin blocked HPK1 caused Axl degradation. In 293T cells, 
pCMV-Axl was transfected alone or together with pCI-HPK1. Then the lysosome 
function was inhibited by 100µg/mL of leupeptin for overnight.  Axl and HPK1 protein 
levels were detected by Western blotting using antibody specific to Axl and HPK1 
respectively. (b) Relative protein levels of Axl in each sample were quantified by Image J 
software. Mean values of multiple experiments were calculated and plotted on a bar 
histogram. When leupeptin was not present, HPK1 down regulated Axl levels to 10.1% 
of control. However, when leupeptin was added, the Axl protein levels came back to  
58% of the control. (c and d) Endocytosis inhibitor Baflomycin A1 blocked HPK1 caused 
Axl degradation.  Same experimental procedure as described in (b and c) was adopted 
here. Final concentration of Baflomycin A1 was 0.1µM. (e and f). (e and f) Endocytosis 
inhibitor Monensin (100µM) blocked HPK1 caused Axl degradation.  
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HPK1 interacts with dynamin. 
Dynamin is a member of GTPase family. The major function of dynamin is to polymerize 
around the neck of invaginated plasma vesicles. Through GTPase activity, Dynamin cuts 
off vesicles from plasma membrane 325, 326. Besides GTPase domain, dynamin has middle 
domain (MD), GTPase effect domain (GED), pleckstrin homology (PH), proline-rich 
domain (PRD), and SH3-like domain 325, 326. All those domains not only are required for 
normal dynamin function, but also provide docking sites for some binding partners 325 326. 
Dynamin includes 3 conserved homologous called dynammin 1, 2 and 3 325, 326, 327. 
Dynamin 1 is exclusively expressed in neuron cells. Dynamin 3 is highly expressed in 
testis tissue. Dynamin 2 is commonly expressed in each type of cells 328, 329, 327. 
 
Previous research found that dynamin directly interacted with HIP-55, which is involved 
in receptor endocytosis 225, 311, 312. HIP-55 was firstly identified as a HPK1 interacting 
protein 313, implying that HPK1, HIP-55, and dynamin may form a protein complex. 
Interestingly, our antibody array data demonstrated that dynamin 2 was a binding partner 
of HPK1 (Fig.11a). To further confirm that HPK1 associated with dynamin. 10µg of pCI-
Flag-HPK1 was transfected into 293T cells which were grown in Ф10cm culture plates. 
Cells transfected with 10µg of pcDNA3.1(+) plasmids served as negative control. 36 
hours after transfection, 293T cells were collected for co-immunoprecipitation assay with 
either anti-dynamin antibody, or normal rabbit IgG. The immunoprecipitated HPK1 was 
detected by Western blotting.  As shown in Fig. 17, significant amount of HPK1 was co-
immunoprecipitated with anti-dynamin antibody but not normal rabbit IgG.  
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Figure 17. HPK1 physically bound to dynamin.  
HPK1 expression plasmid pCI-HPK1 or vector control pCDNA3.1(+)  were transfected 
into 293T cells respectively.  Cell lysates were collected for co-immunoprecipitation with 
anti-dynamin (Dyn) antibody, using normal rabbit IgG as control. Immunoprecipitated 
protein was detected by Western blotting using antibody specific to HPK1 or dynamin. 
Anti-Dyn but not normal IgG pulled down a significant amount of HPK1.
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Dynamin is phosphorylated by HPK1.  
In order to test whether HPK1 can phosphorylate dynamin, Protein of HPK1, kinase dead 
form M46, HPK1-KD, HPK1-CD was obtained as described above for in vitro HPK1 
kinase assay with Axl as a substrate. Endogenous dynamin was collected form 293T cells 
by immunopreciptation with anti-dynamin antibody. HPK1 in vitro kinase assay 
demonstrated that HPK1 and HPK1-KD, but not M46 and HPK1-CD could 
phosphorylate dynamin (Fig. 18a).  
 
To test whether HPK1 can phosphorylate dynamin in vivo, 10µg of pCI-Flag-HPK1, pCI-
flag-M46, or pcDNA3.1(+) (transfection conrol) was transiently transfected individually 
into 293T cells. Proteins having phospho-Thr residue(s) were immunprecipitated by anti-
phospho-Thr antibody. The amount of dynamin in imunoprecipitated protein pool was 
detected by Western blotting. Experiment results demonstrated that the amount of 
phospo-Thr-dynamin was significantly higher in 293T cells transfected with pCI-Flag-
HPK1 than cells transfected with either pCI-Flag-M46, or pcDNA3.1(+) (Fig. 18b). 
Therefore, our data showed that dynamin was phosphorylated on Thr residue(s) by HPK1.  
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Figure 18. HPK1 phosphorylated dynamin (Dyn).  
(a) HPK1 physphorylated Dyn in vitro. An in vitro kinase assay was performed by 
mixing HPK1, M46, Kinase domian (HPK1-KD), C-terminal domian (HPK1-CD) with 
dynamin respectively when 32γ-ATP was added. All HPK1 proteins were 
immunoprecipiated by M2 Beads from 293T cells with corresponding transiently 
overexpressed protein. Endogenous dynamin was immunoprecipitated from 293T cell 
lysates by anti-Dyn antibody. The results demonstrated that HPK1 and HPK1-KD can 
phosphorylate dynamin. (b) HPK1 phosphorylated dynamin in vivo. 293T cells were 
transfected with either pCI-HPK1, pCI-M46, or pCDNA vector control. Proteins with 
phosphorylation on thronine were immunprecipitated with anti-phospho-Thr antibody. 
The immunoprecipitated dynamin were detected by Western blotting. When HPK1 was 
present, significantly more phosphorylated dynamin was co-immunoprecipitated.  
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Dynamin is required for Axl degradation 
As described above, dynamin was required for receptor internalization which is the initial 
step for receptor entering endosomal sorting 326, 327, 330. Disrupting of dynamin function 
would be expected to block Axl internalization and further lysosomal degradation. 
Dyanmin-K44A, a dominant negative form, loses affinity to GTP, and inhibits receptor 
internalization 331, 332. To test whether HPK1 caused Axl degradation is through receptor 
internalization or endocytosis pathway, 0.3µg of pCMV-Axl was co-transfected with 
pCI-Flag-HPK1 (0.5µg), dynamin-K44A (0.5, or 1µg), or both. 24 hours after 
transfection, Axl levels in cells were tested by Western blotting. As shown in Fig. 19, 
When dynamin-K44A was overexpressed, HPK1 mediated Axl protein degradation was 
completely blocked, suggesting dynamin is required for Axl internalization, and further 
confirmed that endocytosis pathway was involved in HPK1 mediated Axl degradation.  
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Figure 19. HPK1 mediated Axl degradation was blocked by dominant negative 
dynamin K44A .  
In 293T cells, HPK1, Axl, or in combination with dynamin K44A was transiently 
overexpressed. Axl protein levels were checked with Western blotting assay. When 
dynamin K44A was present, HPK1 mediated Axl degradation could not be observed.     
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Discussion 
We found Axl is overexpressed in PDA tissues and cell lines. However, the molecular 
mechanism of Axl up-regulation is unclear. HPK1 served as tumor suppressor in 
pancreatic cancer 164. The molecular mechanism how HPK1 suppress pancreatic cancer 
development was unknown either. Our research demonstrated that HPK1 physically 
associated with Axl, which was demonstrated by an antibody array assay (Fig. 11a), and 
a reciprocal co-immmunoprecipitation assay (Fig. 11b). Physically association between 
Axl and HPK1 was further confirmed by identifying that C-terminal domain of HPK1 
bond to Axl. HPK1 phosphorylated Axl by an in vitro kinase assay. Whether HPK1 
directly interact Axl and whether HPK1 itself phosphorylate Axl need to be determined 
with purified proteins. 
 
Axl protein levels were found to be down-regulated by overexpressed HPK1 but not M46 
in a dose dependent manner (Fig. 14). Other than to attenuate T cell receptor (TCR) 
signaling by phosphorylating SLP-76 151, we are the first to demonstrate that HPK1 may 
attenuate Axl receptor signaling. Axl was further found to be down regulated by HPK1 
through decreasing Axl protein half-life (Fig. 15a and b). However, Axl mRNA levels, 
reflected by quantitative real time PCR, were not altered by HPK1 (Fig. 15c). Such 
findings implied that phosphorylation of Axl by HPK1 may lead Axl to protein 
degradation system.     
 
Here we investigated the mechanisms of Axl degradation caused by HPK1. One major 
way to degrade receptors, which are located on plasma membrane, is going through 
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endocytosis/lysosome pathway. Receptors are first internalized, and then delivered to 
lysosome through early and late endosomes 333, 193, 316. In order to test the roles of 
endocytosis/lysosome pathway in HPK1 induced Axl degradation, we treated cells with 
proteinase inhibitor leupeptin. Leupeptin inhibited HPK1 mediated Axl degradation, 
suggesting lysosome was involved in HPK1 mediated Axl degradation.  Since receptors 
are delivered to lysosome through endosomal sorting, we expect that inhibiting endosome 
functions will also block HPK1 mediateded Axl degradation. Consistent with this notion,  
endocytosis inhibitors bafilomycin A1, and monensin inhibited HPK1 mediated Axl 
degradation. The roles of endocytosis in HPK1 mediated Axl degradation was further 
confirmed by the fact that dominant negative dynamin-K44A completely abolished 
HPK1 mediated Axl degradation. Therefore, HPK1 down regulates Axl protein 
expression in PDA through endocytosis/lysosome pathway.  
 
Interestingly, we found that HPK1 also physically associated with dynmain 2 in Panc-1 
cells by an antibody array assay (Figure 11a). Dynamin 2 has same function as dynamin 1. 
The difference is that dynamin 2 is expressed in all types of cells, whereas dynamin 1 is 
exclusively expressed in neuron cells 329 328. The absence of dynamin 1 in Panc-1 cells 
can explain why dynamin 1 was not detected to associate with HPK1 in same antibody 
array assay. A co-immunoprecipitation assay with anti-dynamin 2 antibody further 
confirmed that HPK1 physically associate with dynmin 2. Previous research showed that 
dynamin directly bond to HIP-55, a molecule involved in endocytosis 225. HIP-55 has 
been identified as a direct binding partner of HPK1 226, 313. So HPK1 may form a 
complex with HIP-55 and dynmin. HPK1 may also go through Grb2 to bind to dynamin. 
123 
 
Grb2 has also been identified to bind directly with either HPK1, or dynmain 334, 335, 336. 
Both HIP-55 and Grb2 are adaptor proteins containing SH3 domains. HPK1 may directly 
interact with dynamin or interact with dynamin through HIP-55, or Grb2. Our in vitro 
kinase assay with immunoprecipiated HPK1 complex and dynamin 2 complexe 
demonstrated that HPK1 can phosphorylate dynmain (Fig. 18). Moreover, we found that 
HPK1 can phosphorylate threonine amino acid on dynamin in vivo (Fig 18). Because 
HPK1 kinase dead form M46 could not increase the amount of phospho-Thr-dynamin, 
combining with the phenomenon that HPK1 physically associated with dynamin, it 
further suggested that dynamin may be a substrate of HPK1.  
 
In summary, we found that HPK1 could cause Axl degradation. An endocytosis coupled 
lysosome pathway was required for HPK1 caused Axl degradation. In future direction, 
we will put more efforts on determining whether HPK1 caused Axl degradation 
contributes to pancreatic cancer progression. In order to keep a close mimic of 
physiological condition, Gas6 will be added to pLVX-HPK1-Panc-1 cells with or without 
Dox which induced HPK1 expression. Then the cell proliferation, migration/invasion, or 
resistance to apoptosis stimuli will be measured and compared. When HPK1 is present, 
Gas6 induced cell proliferation, survival, migration, or invasion is supposed to be less, 
compared to when HPK1 was absence. This part of experiment will answer the 
physiological significance of HPK1 mediated Axl degradation. 
 
Though we found that HPK1 could phosphorylate Axl, and dynamin, there are still many 
remaining questions about molecular mechanisms of Axl degradation. So far we don’t 
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know which site(s) of Axl is phosphorylated by HPK1. To identify the phosphorylation 
sites, we will purify recombinant protein of Axl. After in vitro kinase assay with HPK1, 
the phosphorylation sites on Axl will be analyzed by mass spectrometry 337. The 
identified phosphorylation site(s) will be mutated to check whether phosphorylation is 
required for HPK1 caused Axl degradation. The mutants which could not be 
phosphorylated by HPK1 also can be used to address whether HPK1 caused Axl 
degradation contributes to pancreatic progression.  
 
Another big question is how Axl phosphorylation by HPK1 leads to lysosommal 
degradation. It has been reported that Ser/Thr phosphorylation in receptor cytoplasmic 
tail regulates receptor internalization. Phosphorylation on Ser1046/7 sites is required for 
EGFR internalization 338. Phosphorylation by p38 cause accelerated EGFR internalization 
198, 339. Whether HPK1 regulate Axl internalization is an immediate question needing 
answers. For address this question, Gas6 will be labeled by rado-isotope, the Gas6 
internalization rate will be measured when HPK1 is present or not. In case of EGFR 
degradation, ubiquitination of EGFR by Cbl E3 ligase play an important role. After EGF 
binding to EGFR, EGFR become dimerized and activated through trans-phosphorylation 
on tyrosine sites. Then Cbl is recruited through adaptor protein Grb2. Ubiquitin on EGFR 
provides a recognition site for ubiquitin-interacting motifs contained proteins, like Eps15, 
Eps15R and Epsins, which are components of endosytosis machineries193, 340-343. In 
Human lens epithelial cells (HLEC), Gas6 treatment caused Axl degradation, 
accompanied with Gas6 induced Axl-Cbl interaction, and Axl ubiquitination. Gas6 
caused Axl degradation was blocked by endocytosis inhibitors 344. Whether Axl 
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phosphorylation by HPK1 can increase Cbl recruitment and Axl ubiquitination is yet to 
be determined.  
 
Due to its unique role in vesicle scission, dynamin occupied a critical position in 
endocytosis 345. Accumulated evidences revealed that dynmain polymerization is a 
strictly regulated process 346, 347, 348. Dynamin itself is a highly phosphorylated protein 349. 
Phosphorylation of dynamin by PKC dramatically increases dynamin GTPase activity 350 
351. Re-phosphorylation by cdk5 assures that dynmain can be reused in next round of 
internalization 352, 353. However, the role of many other identified phosphorylation sites 
on dynamin and the kinase involved in dynamin phosphorylation are unknown. Here, we 
found dynamin can be phosphorylated by HPK1 both in vitro and in vivo. Whether and 
how dynamin phosphorylation by HPK1 contributes to Axl internalization will be another 
interesting aspect to pursue. Identification of phosphorylation sites on dynamin by HPK1 
will help to address above issue. An immediate question that we can answer is whether 
phosphorylation by HPK1 affects dynamin GTPase activity and dynamin polymerization 
capability. One more interesting thing is that when cells are stimulated with EGF, 
dynamin was phosphorylated on some tyrosine sites 354, which is required for EGFR 
internalization. Gas6 is expected to have same effects as EGF on dynamin 
phosphorylation. Whether HPK1 down regulate Gas6 caused dynamin phosphorylation 
on tyrosine sites is another interesting question to answer. In a word, those experiments 
will answer how HPK1 affects dynamin function to degrade Axl protein. A model 
proposed for HPK1 mediated Axl degradation is displayed in Fig. 20.  
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Figure 20. Model of HPK1 mediated Axl degradation through endocytosis/lysosome 
pathway. 
HPK1 interacts with and phosphorylates dynmain. Phosphorylated dynamin promotes 
Axl internalization rate. Internalized Axl will be sequentially delivered to early endosome, 
late endosome, and then lysosome, where Axl is finally degraded.  
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Toward a more comprehensive understanding of the influence on pancreatic cancer 
progression by HPK1 mediated Axl degradation, we will check Axl down-stream 
signalings potentially affected by HPK1. Since the highly conserved activation 
mechanism of Akt adopted by Axl and EGFR 120, 229, we expect HPK1 can also attenuate 
Gas6 stimulated Akt activity.  Other Axl down-stream effectors, like ERK, MAPK, SRC, 
and PKC, will also be considered as test objects 80.  However, we may not anticipate 
HPK1 will bring similar impacts on all Axl down-stream effectors  355, 356, 357. Those 
works will further answer the biological significance of HPK1 mediated Axl degradation 
in PDA cells.    
 
Since stabilizing HPK1 expression in Panc-1 cells caused Axl degradation (Fig. 14b), 
down-regulating Gas6/Axl signaling could be one approach adopted by HPK1 to function 
as tumor suppressor in PDA 164. The loss of HPK1 in PDA is going through proteasome 
pathway 164. Inhibiting proteasome pathway in PDA is one potential way to down 
regulate Axl expression and further improve clinic outcomes of PDA patients.  
 
In a word, our research for the first time demonstrated that Axl protein degradation could 
be through endocytosis/lysosome pathway. HPK1 is firstly found to down regulate Axl 
expression through endocytosis/lysosome pathway. Since HPK1 was found to interact 
with and phosphorylate dynmain, HPK1 can be a component of endocytosis pathway. 
Our research enriched the knowledge that HPK1 can function as a negative regulator of 
receptor more than activating the JNK pathway 314, but can directly modulate receptor 
expression. Our research demonstrated that, except inhibiting the Axl kinase activity, 
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accelerating Axl degradation through endocytosis/lysosome pathway will be an 
interesting direction to consider for its application in PDA therapy. Morover, how HPK1 
participate in endocytosis/lysosome pathway is needed to be investigated more in the 
future.                 
130 
 
Summary 
Our general goal is to understand the molecular mechanism of pancreatic ductal 
adenocarcinoma (PDA) development, and identify potential therapeutic molecular targets. 
Here, we found receptor tyrosine kinase Axl is overexpressed in 70% of PDA patients 
and 75% of PDA cell lines. Axl overexpression correlates with shorter overall survival 
time of PDA patients, and severer distant metastasis. In PDA mouse model, Axl 
overexpression is early event happened in chronic pancreatitis. Silencing Axl by shRNA 
sensitizes PDA cells to apoptosis stimuli, and decreases the cell migration/invasion 
potential. Axl silencing abolishes ligand Gas6 stimulated Akt activation and decreases 
secreted MMP-2 levels and NF-κB activity, all of which have oncogenic function in PDA 
tumorigenesis. Our research successfully demonstrated that Axl can be a useful 
prognostic marker of PDA patients and Axl can be developed as therapeutic target.  
 
During the process of investigating the molecular mechanism of Axl up-regulation in 
PDA, we found hemopoietic progenitor kinase 1 (HPK1) interacts with and 
phosphorylates Axl. HPK1 down regulates Axl protein levels through decreasing Axl 
protein stability. Restoring HPK1 expression in PDA cell reduces Axl expression. 
Endocytosis/lysosome pathway is involved in HPK1 mediated Axl degradation. HPK1 
binds to and phosphorylates dynamin, a crucial component of endocytosis pathway. 
Dominant negative form of dynamin completely blocks HPK1 mediated Axl degradation. 
Since HPK1 is degraded by proteasome pathway in PDA, besides directly inhibiting Axl 
kinase activity, inhibiting proteasome pathway provides one more option to decrease Axl 
protein levels and further to slow down PDA progression.                     
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